November is both Pancreatic Cancer Awareness Month and Stomach Cancer Awareness Month – two cancer types greatly in need of new treatment options. We’re advancing a clinical trial of #adc SOT109 as a potential therapeutic option for gastrointestinal cancers. SOT109 targets CDH17, a protein abundantly expressed in GI cancers, including CRC, stomach, pancreatic, and esophageal cancers.
We remain committed to advancing innovative therapies with the potential to make a difference for patients.
#pancreaticcancerawareness #stomachcancerawareness #oncology #cancer
SCTbio
SCTbio (legally: SCT Cell Manufacturing s.r.o.) is a Czech biotechnology company that provides contract development and manufacturing (CDMO) services for Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapy products. More on Wikipedia
-
SOTIO
@SOTIO
-
SOTIO
@SOTIO
Our Chief Scientific Officer Amy Jensen-Smith has been recognized by @HealthTechRPT as one of this year’s Top Women Leaders in Biotech and Life Sciences! Since joining SOTIO more than five years ago, Amy has played an instrumental role in advancing our scientific vision and pipeline. From leading global discovery and preclinical research to helping guide our next-generation #adcs toward clinical development, her scientific leadership continues to shape what’s ahead for SOTIO. Congratulations, Amy, on this well-deserved recognition!
See the report: thehealthcaretechnologyreport.com/the-top-women-leaders-i… -
SOTIO
@SOTIO
We’re on the ground at #sitc26 and looking forward to presenting the first clinical data on SOT201, our PD-1 targeting IL-15 immunocytokine. Interim data from the Phase 1 VICTORIA-01 clinical trial show early evidence of durable antitumor activity with SOT201, including responses in patients whose #cancer had progressed after checkpoint inhibitor therapy.
Read more in today’s press release: sotio.com/news-publications/news/sotio-presents-initial-d…
@sitcancer
#cancerimmunotherapy #immunocytokine #drugdevelopment #clinicaltrials -
SOTIO
@SOTIO
This month we are heading to @EBDgroup’s #bioeurope2026 in Germany to connect with potential collaborators and explore opportunities to advance our oncology pipeline.
With two next-generation ADC programs in development for solid tumors, we’re interested in conversations around partnering, licensing, and investment with companies and investors focused on bringing differentiated cancer therapies to patients.
If you would like to arrange a meeting with our BD team, please reach out to partnering@sotio.com.
#biotechpartnering #adc #oncology -
SOTIO
@SOTIO
Next week at #sitc2026 we will present initial data from VICTORIA-01, our Phase 1 study evaluating SOT201 in patients with advanced or metastatic solid tumors. SOT201 is a novel cis-acting immunocytokine, combining IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells. We’re looking forward to engaging with the #cancerimmunotherapy community and sharing these promising data.
@sitcancer #immunotherapy -
SOTIO
@SOTIO
Cadherin-17, or #cdh17, is a clinically-validated target highly prevalent across gastrointestinal cancers, with expression in the vast majority of colorectal cancer (#crc) primary tumors and metastases, as well as a substantial proportion of primary gastric tumors. With limited expression outside the GI tract, CDH17 represents an attractive target for precision therapies like antibody-drug conjugates (#adcs).
CDH17 is the target of SOT109, our next-generation #adc designed for GI cancers, which recently entered the clinic in the Phase 1/2 CADENCIA-01 clinical trial.
We’re pleased to be recognized by @PharmaVoice as a frontrunner in the CDH17 space. Read more about the emerging drug targets pharma is betting on next: www.pharmavoice.com/news/emerging-drug-targets-cancer-inf…
#oncology #drugdevelopment #colorectalcancerinnovation -
SOTIO
@SOTIO
Our CSO Amy Jensen-Smith, Ph.D., sat down with the @medicine_maker to discuss her path from bench to scientific leadership, and what it takes to build teams where curiosity, experimentation and learning are part of the process.
Amy has worked in academia, at @theNCI, in big pharma and now in biotech. Along the way, she’s seen the value of academic freedom, the importance of staying close to patients, and why biotech can offer the resources and focus needed to move new ideas forward.
That thinking shapes how we approach drug development at SOTIO. Rather than working through every question in order, we look for the question that could stop a program and test it first. By tackling the biggest risks early, we can see what’s worth pursuing and what isn’t.
Read the full conversation below.
#adc #oncology #drugdevelopment #womeninscience
The Medicine Maker
@medicine_maker
What if the smartest move in drug development is knowing when to walk away?
SOTIO Biotech's Amy Jensen-Smith explains why testing a drug program's biggest weakness first could save time and resources.
🔗 themedicinemaker.com/issues/2026/articles/october/find-th…
#drugdiscovery #biotech -
SOTIO
@SOTIO
Our CADENCIA-01 Phase 1/2 clinical trial evaluating our potentially best-in-class #adc SOT109 has been featured among the “five new colorectal cancer clinical trials you should know about” in @cure_today.
Dosing the first patient last month marked an important step as we advance SOT109 into the clinic and begin generating initial clinical data. As the only CDH17-targeting ADC that has been granted U.S. @FDA Fast Track Designation, SOT109 is uniquely positioned within the emerging CDH17 landscape and has the potential to become a differentiated treatment option for patients with advanced gastrointestinal cancers.
Read the full article: www.curetoday.com/view/5-new-colorectal-cancer-clinical-t…
#oncology #drugdevelopment -
SOTIO
@SOTIO
We’re heading to #esmo26! As we continue to advance our portfolio of clinical-stage #adcs for difficult-to-treat solid tumors, we look forward to discussing emerging oncology trends and exploring opportunities for collaboration with potential partners at the @myESMO Congress.
Please reach out to partnering@sotio.com if you’re interested in connecting.
#esmo26 #adc #oncology #biotech #drugdevelopment #partnering -
SOTIO
@SOTIO
At @World_ADC San Diego, Martin Vodak looks forward to connecting with companies and investors to discuss the future of antibody-drug conjugates (#adcs) for the treatment of solid tumors.
With two ADC programs entering the clinic in 2026, we’re advancing targeted therapies designed to address significant unmet needs in #crc and #sarcoma, with the potential to deliver new treatment options for patients.
#worldadc #worldadcsandiego #drugdevelopment #oncologyinnovation -
SOTIO
@SOTIO
Next month, the Life Science Legal Strategy Summit, organized by @KisacoRes, brings together legal, IP, and life sciences professionals from across the industry. SOTIO's Christoph Rehfuess will join fellow experts for a panel discussion on strategies for protecting antibody innovation across Europe and the U.S. As the legal landscape for biologics continues to evolve, the session will explore key considerations for securing robust IP portfolios.
#lsls2026 #lifesciences #patentstrategy #drugdevelopment -
SOTIO
@SOTIO
Today is World Cancer Research Day, recognizing the discoveries driving progress in #cancer care. Across SOTIO’s ADC platform, one focus of our research has been expanding the therapeutic window of these therapies.
The therapeutic window is the dose range of a medicine that provides effective therapy and avoids serious side effects. A wider therapeutic window means more flexibility in dosing and a larger safety margin.
Our research aims to expand our ADC candidates’ therapeutic windows by innovating in target identification, linker technology, and antibody design – with the end goal of creating safe and effective therapies for cancer types with very few treatment options today.
Learn more about our ADC research: sotio.com/pipeline/antibody-drug-conjugates/technology
#worldcancerresearchday #cancerresearch #oncology #adc -
SOTIO
@SOTIO
SOT106 has received two additional designations from @FDA: Orphan Drug Designation for #softtissuesarcoma and Fast Track Designation for #osteosarcoma.
Our potentially best-in-class investigational ADC targeting LRRC15 now holds both designations for both primary types of sarcoma. With a first-in-human clinical trial expected to begin later this year, SOTIO is advancing development of SOT106 with the hope of delivering a targeted therapy with benefit across sarcoma subtypes. Read more in today’s press release: sotio.com/news-publications/news/sotio-advances-sot106-wi…
#fasttrackdesignation #orphandrugdesignation #adc #sarcoma -
SOTIO
@SOTIO
Next week, we will be at the ADC Symposium here in our home city of Prague. Zuzana Antošová, Director, Bioanalysis & Pharmacokinetics, will deliver an oral presentation exploring how ADC stability and species-specific biology influence pharmacokinetics, safety, and the translation of preclinical findings into human PK prediction. We look forward to joining colleagues in conversations at the cutting edge of ADC drug development!
#adc #drugdevelopment -
SOTIO
@SOTIO
Today we announced that the first patient has been dosed in our Phase 1/2 CADENCIA-01 study evaluating SOT109, a next-generation antibody-drug conjugate (#adc) targeting cadherin-17 (CDH17) for the treatment of colorectal cancer. This milestone reflects our continued commitment to advancing innovative therapies with the potential to expand treatment options and improve outcomes for people living with CRC and other GI cancers. Read more in today’s press release: sotio.com/news-publications/news/sotio-doses-first-patien…
#firstpatientdosed #fpd #trialinitation #colorectalcancerinnovation #drugdevelopment #clinicaltrials -
SOTIO
@SOTIO
Thank you for your visit and the insightful discussion, @USEmbassyPrague!
U.S. Embassy Prague 🇺🇸🇨🇿
@USEmbassyPrague
„Nadějná léčba proti rakovině se vyvíjí jak v Praze, tak v Bostonu. 🚀 Skvělá návštěva pražské centrály společnosti @SOTIO! 🇨🇿🇺🇸 Tato česká společnost s pobočkou v Bostonu spojuje špičkový výzkum, inovace v biotechnologii a onkologii. Děkuji za inspirativní diskusi!“ 🧬🔬💊 #ambmerrick
-
SOTIO
@SOTIO
The U.S. Food and Drug Administration (@FDA ) has accepted our investigational new drug (IND) application for SOT106, enabling a first-in-human Phase 1/2 trial in patients with #osteosarcoma and soft tissue sarcoma. SOT106 is an investigational antibody-drug conjugate (#adc) targeting LRRC15, a clinically validated target broadly expressed across multiple highly prevalent #sarcoma subtypes. Sarcomas are a diverse group of cancers with limited targeted treatment options, and this milestone moves a potential best-in-class therapy one step closer to patients with sarcoma and other LRRC15-positive malignancies. We look forward to sharing additional updates as SOT106 advances into clinical development.
#indacceptance #drugdevelopment #clinicaltrials #oncologyresearch -
SOTIO
@SOTIO
The U.S. Food and Drug Administration (@FDA ) has granted Fast Track Designation to SOT106, our potentially best-in-class investigational antibody-drug conjugate targeting leucine-rich repeat-containing 15 (#lrrc15), for the treatment of #softtissuesarcoma. This designation underscores the significant unmet need for soft tissue sarcoma and the potential of SOT106 to bring a targeted #adc approach to patients with few options today. It follows the Orphan Drug Designation granted to SOT106 for osteosarcoma in May, further supporting its development across sarcoma. Read more in today's press release: www.sotio.com/news-publications/news/fda-grants-fast-trac…
#fasttrackdesignation #ftd #sarcoma #drugdevelopment -
SOTIO
@SOTIO
Proud to see our Chief Scientific Officer, Amy Jensen-Smith, featured in @bizwomenreports' "In Her Own Words" series. In the essay, Amy reflects on the pivotal moment that set her on the path to cancer drug development, reflects on her journey from bench scientist to Chief Scientific Officer, and explains why the greatest challenges within the solid tumor treatment paradigm remain her biggest motivation. From helping bring CAR-T therapies from early breakthroughs to approved treatments, Amy now leads the advancement of our ADC pipeline, advancing a portfolio of antibody-drug conjugates for the treatment of various solid tumors. Her scientific leadership shapes how we pursue better options for the patients who need them most. Read her story: www.bizjournals.com/bizwomen/news/mentoring-matters/2026/…
#oncology #cancerresearch #womeninscience #biotech #drugdevelopment #adc -
SOTIO
@SOTIO
This #nationalinternday we’re proud to recognize the talented students who have spent their summer at SOTIO through the Erasmus + program, including students from @imc_krems , @UofGlasgow , @VSCHT , and @science_charles . Their curiosity and eagerness to learn are part of what makes scientific research so rewarding. Thank you to our interns for all of your contributions, and to the SOTIO mentors who have helped support and inspire the next generation of scientists.
#biotechinterns #internship #companybuilding -
SOTIO
@SOTIO
Behind every advancement in sarcoma treatment research are the scientists and clinicians working to deepen our understanding of these challenging diseases. This #sarcomaawarenessmonth, we’re revisiting Amy Jensen Smith’s reflections on how the complexity of sarcoma continues to shape her work in oncology and why advancing new treatment approaches remains so important for patients. Read the full byline below.
#sarcomainnovation #sarcomaresearch #drugdiscovery
SOTIO
@SOTIO
In the article below, Chief Scientific Officer, Amy Jensen-Smith, shares her perspective on the urgent unmet need in #sarcoma and why advancing researching in this complex disease area is so critical, especially on #rarediseaseday.
SOTIO is committed to developing precision-based therapies for sarcoma, exemplified through SOT106, our investigational antibody-drug conjugate (#adc) targeting LRRC15, a clinically validated target broadly expressed across sarcoma subtypes.
👉 www.linkedin.com/posts/amy-jensen-smith-08619218_raredise…
#rarediseaseday2026 #rarediseases #rarecancers #oncologydevelopment -
SOTIO
@SOTIO
Today we announced the @EPOorg Boards of Appeal have upheld European Patent EP 3 444 271 B1, confirming intellectual property protection for SOT201, our next-generation PD-1-targeting immunocytokine. SOT201 is currently being evaluated in our Phase 1 VICTORIA-01 study in patients with advanced solid tumors. This decision reinforces the strength of SOT201 as it continues to show a high disease control rate, including objective responses in heavily pre-treated cancer patients. Read the full press release here: www.sotio.com/news-publications/news/european-patent-offi…
#immunocytokine #patentprotection #drugdevelopment #clinicaltrials -
SOTIO
@SOTIO
The @US_FDA has granted Fast Track Designation to SOT109, our next-generation antibody-drug conjugate targeting cadherin-17 (#cdh17) for the treatment of #colorectalcancer (CRC). This designation recognizes the crucial need for new treatment options for patients with #crc and the promise of SOT109 to extend targeted #adc therapy to a substantially broader patient population. Read more in today’s press release: sotio.com/news-publications/news/fda-grants-fast-track-de…
#fasttrackdesignation #ftd #colorectalcancerinnovation #drugdevelopment -
SOTIO
@SOTIO
Prague is earning recognition as one of Central Europe’s fastest-growing biotech hubs, and we’re excited to be part of the story. In the recent installment of @Labiotech_eu series spotlighting biotech ecosystems around the world, Prague is recognized for its world-class science, expanding innovation ecosystem, and growing global investment. The article highlights SOTIO as the largest Czech biotech company, alongside the many organizations helping drive the region’s momentum. We’re proud to contribute to Prague’s thriving life sciences community as we continue advancing next-generation targeted #cancertherapies that could benefit patients around the world.
www.labiotech.eu/in-depth/prague-biotech-hub/
#praguebiotech #drugdevelopment #oncologyinnovation -
SOTIO
@SOTIO
July is #sarcomaawarenessmonth, dedicated to recognizing the impact of these rare and complex cancers. At SOTIO, we’re rapidly advancing our investigational antibody-drug conjugate SOT106 with plans to enter the clinic later this year. SOT106 recently received Orphan Drug Designation (#odd) from the U.S. @FDA , underscoring both the urgent need for new sarcoma therapies and the potential of this program.
#adc #sarcomainnovation #rarecancer #raredisease #oncologyinnovation -
SOTIO
@SOTIO
Our investigational new drug (IND) application for SOT109 has been accepted by the @FDA for the treatment of colorectal cancer. SOT109 is an investigational antibody-drug conjugate (#adc) targeting CDH17, which is expressed in over 90% of CRC cases. This milestone marks an important step forward in advancing a potential new targeted treatment option with best-in class properties for patients with CRC and other GI cancers. We look forward to sharing additional updates as we progress toward clinical development and key trial milestones.
#indacceptance #drugdevelopment #clinicaltrials #oncologyresearch -
SOTIO
@SOTIO
Next week, SOTIO is heading to San Diego for the BIO International Convention 2026 (@IAmBiotech ). We’re looking forward to joining potential partners, life science investors, and industry peers to discuss the latest developments in #antibody-drug conjugates, including our #adcs for treating solid tumors. Please reach out to Norbert Prenzel if you are attending and interested in connecting.
#drugdevelopment #biotechpartnering #bio2026 #oncology -
SOTIO
@SOTIO
Two wheels, many kilometers, and a shared commitment to sustainability! For the 9th year, SOTIO and SCTbio colleagues joined the ‘Bike To Work’ initiative. This year, 26 participants covered a total of 8,400 km, helping to reduce roughly 1,374 kg of CO2 emissions and supporting a more sustainable communing culture. Congratulations to this year’s top performers: Irena Kabátova (613.37 km) and Christian Frantz (933 km).
Team Slowrider, consisting of Petra Svobodová, Adam Těhník, Martin Pávek, Aleš Slavíček and Jakub Lipovský, took first place with 2,335.82 km. Team Kološlapky followed with 2,084 km, and Team Kolohnáti with 1,601.5 km. Thanks to everyone who participated!
#sustainability #biketowork -
SOTIO
@SOTIO
Cancer Immunotherapy Month represents a meaningful moment to reflect on the progress being made in #cancer treatment and the continued need for innovation across modalities. Our work continues to span immuno-oncology and targeted therapies, including our next-generation PD-1 targeting #immunocytokine, SOT201, which is designed to reinvigorate exhausted T cells in tumors.
#cancerimmunotherapymonth #immunooncology #cancerresearch -
SOTIO
@SOTIO
New findings from the SOTIO research team, published in @tandfonline , highlight the potential of SOT201, a novel cis-acting PD-1/IL-15 mutein-based #immunocytokine, currently in development for the treatment of solid tumors. The study further demonstrates how targeted delivery of IL-15 signaling to PD-1+ T cells have the potential to help reinvigorate anti-tumor immune responses within the tumor microenvironment, supporting a differentiated approach to cytokine-based cancer immunotherapy. Read the report here: www.tandfonline.com/doi/full/10.1080/13543784.2026.2683841
#oncologyinnovation #immunotherapy #cancerresearch -
SOTIO
@SOTIO
SOTIO will present research at the upcoming @EACRnews 2026 congress, exploring predictors of response to neoadjuvant anti-PD-1–based chemo-immunotherapy in non-small cell lung cancer (#nsclc) using integrated spatial and immune profiling approaches. These findings highlight associations between pre-existing immune-active CD8+ T-cell populations, tertiary lymphoid structures, and treatment response, suggesting that baseline tumor immune characteristics may influence sensitivity to therapy.
#eacr2026 #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
The @US_FDA has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma. SOT106 is a potential best-in-class antibody-drug conjugate (#adc) for sarcoma, targeting LRRC15, a clinically validated target frequently expressed across multiple #sarcoma subtypes. This designation recognizes the significant unmet need for targeted therapies against this rare and aggressive #cancer. We look forward to bringing SOT106 into the clinic in the second half of this year. Read the full announcement here: sotio.com/news-publications/news/sotio-receives-u-s-fda-o…
#drugdevelopment #sarcomainnovation #orphandrug -
SOTIO
@SOTIO
Colorectal cancer (#crc) is a significant global heath challenge, with many patients facing limited treatment options. According to @CancerResearch , colon cancer is now a leading cause of cancer-related death in young people. Next-generation #adcs are emerging as a promising approach to treat this challenging cancer. SOT109, our ADC targeting CDH17, is approaching clinical studies as a novel treatment for CRC. Through programs such as SOT109, we’re advancing therapies with the potential to improve outcomes and expand options for patients living with #colorectalcancer.
#oncologyresearch #colorectalcancerinnovation #drugdevelopment -
SOTIO
@SOTIO
We’re proud to see SOTIO’s research published in @NaturePortfolio Communications. The study highlights the potential of NKG2A inhibition to restore NK cell function and strengthen anti-tumor immune responses in #ovariancancer, further advancing the understanding of novel immunotherapy approaches. Congratulations to the researchers and collaborators involved in this important achievement!
Check out more here: www.linkedin.com/posts/jitka-fucikova-699b8a13b_naturecom…
#cancerimmunology #oncologyinnovation #drugdevelopment -
SOTIO
@SOTIO
On #clinicaltrialsday, we join the global research community in celebrating the theme of “Research Rising,” which honors the progress, people, and purpose that drive clinical research forward. At SOTIO, we bring deep expertise in clinical development, working to translate scientific insights into meaningful treatment options for patients. We are advancing a pipeline of #adcs focused on initiating clinical trials for cancers where patients continue to face significant unmet need. Together, we’re helping research rise to meet the needs of today and the promise of tomorrow.
@ACRPDC
#ctd2026 #researchrising #weallrisetogether #drugdevelopment #adcs -
SOTIO
@SOTIO
SOTIO is heading to #asco26! We look forward to engaging with oncology researchers, industry leaders and investors about our #adcs SOT106 and SOT109 entering the clinic later this year. If you’re attending, please reach out to Radek Spisek, CEO, Vivi Boura, CMO, and Martin Vodak, Business Development Senior Director.
#asco26 #biotechpartnering #drugdiscovery -
SOTIO
@SOTIO
Bio€quity Europe 2026, organized by @BioCentury , @EBDgroup and prague.bio, brought together an inspiring community of innovators, investors, and partners from across the global biotech ecosystem to our home of Prague.
Our CEO, Radek Spisek, presented details on our growing pipeline and participated in a panel discussion, making it a valuable opportunity for SOTIO to connect with peers, discuss the latest industry developments, and showcase recent progress across our programs, including our next-gen #adcs.
Check out some snapshots from the event below.
#bioequityeurope #drugdiscovery #oncologyinnovation -
SOTIO
@SOTIO
Next stop – Greece for the @FEBSnews Tumor Microenvironment meeting. SOTIO scientist Artemis Angelidou will present work combining both spatial and immune profiling to help predict response to immunotherapy in non-small cell lung cancer (#nsclc) -- part of our continuing dedication to developing better treatment approaches for solid tumors like lung cancer.
#febs #drugdevelopment #oncologyresearch -
SOTIO
@SOTIO
Next week, Bio€quity Europe, hosted by @BioCentury and @EBDgroup, takes center stage in our hometown.
In addition to participation in the CEO’s discussion panel, Radek Spisek will present recent progress across our development pipeline of next generation #adcs and immunocytokines on Tuesday, May 5th. If you’re interested in connecting please reach out to: partnering@sotio.com and our team attending, Radek Spisek, Norbert Prenzel, Martin Vodak or @RichardKapsa.
#bioequityeurope #drugdevelopment #oncologyresearch #biotechpartnering -
SOTIO
@SOTIO
Radek Spisek, CEO, and Norbert Prenzel, Head of Business Development, are heading to San Diego, CA, for the upcoming @AACR Annual Meeting. As we rapidly expand our clinical pipeline with next-generation #adcs, we look forward to connecting with partners and investors to explore new opportunities for collaboration. If you’re attending and would like to meet, please reach out.
#aacr2026 #biotechpartnering #oncologyinnovation -
SOTIO
@SOTIO
Next month, Prague will welcome the global biotech community for Bio€quity Europe, organized by @BioCentury and @EBDgroup. Our CEO, Radek Spisek, will join a panel discussion focused on a critical topic for growing biotech companies: how to build, support, and retain strong teams across geographies. From competing with established hubs to fostering culture internationally, the session will explore practical approaches to developing talent in an increasingly global landscape.
Learn more about the event here: conferences.biocentury.com/bioequity-europe
#bioequityeurope #drugdevelopment #cancerresearch -
SOTIO
@SOTIO
Norbert Prenzel, Head of Business Development and Licensing, will be in Munich for the upcoming Germany – China Pharma and Life Sciences Collaboration Forum. He’ll join a panel focused on exploring emerging trends in the global BD&L sector, particularly in high-growth areas like #adcs and advanced therapies.
#drugdevelopment #biotechcollaboration #healthcareinnovation -
SOTIO
@SOTIO
Our Business Development team is heading to Lisbon later this month for #bioeuropespring and @LSXLeaders. As we continue to advance our pipeline of next-generation #adcs, we look forward to meeting with potential partners and investors. Please reach out to Martin Vodak or Norbert Prenzel if you’re attending and would like to meet.
@EBDGroup
#bioeurope #biotechpartnering #oncologyinnovation #cancertherapy #lsx -
SOTIO
@SOTIO
Understanding the tumor microenvironment is essential for unlocking new therapeutic strategies in #oncology. At the upcoming @EACRnewsTumour Ecosystem: From Mechanisms to Novel Therapeutics Conference, SOTIO Scientist Cecilia Aquino-Perez will present research on tertiary lymphoid structures in HPV-induced cancers, showing how immune architecture within tumors shapes treatment response. We look forward to sharing our work and engaging with fellow scientists, clinicians, and translational researchers driving progress across the oncology community.
#eacr26 #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
On #internationalwomensday, we acknowledge the important contributions of women across SOTIO and the broader R&D community. Their expertise and leadership strengthen our teams and support the development of innovative, patient‑focused #cancer therapies. To learn more about our culture and meet some of the colleagues driving our mission forward, check out this video: www.linkedin.com/feed/update/urn:li:activity:741682434825…
#iwd2026 #womeninstem #drugdevelopment -
SOTIO
@SOTIO
SOTIO is attending #esmosarcoma next week to meet with others working at the forefront of treating #sarcoma, and share the latest exciting data on our ADC in development for sarcoma, SOT106. Please reach out to our colleagues Vivi Boura or Norbert Prenzel if you’re interested in connecting.
@myESMO
#rarecancers #oncology #drugdevelopment -
SOTIO
@SOTIO
#colorectalcancer is now the leading cause of cancer-related death among people younger than 50 in the U.S. It’s a critical moment for #colorectalcancerawarenessmonth to spread the word and help drive earlier diagnosis and treatment. We’re developing SOT109, a next generation #adc designed to target CDH17, an antigen that is highly expressed in colorectal cancer and other GI cancers. Check out how ADCs like our SOT109 program work to address cancers like colorectal cancer below.
Learn more about colorectal cancer’s rise in the @AmericanCancer recent report: pressroom.cancer.org/under-50-mortality-declines
#drugdevelopment #antibodydrugconjugates -
SOTIO
@SOTIO
In the article below, Chief Scientific Officer, Amy Jensen-Smith, shares her perspective on the urgent unmet need in #sarcoma and why advancing researching in this complex disease area is so critical, especially on #rarediseaseday.
SOTIO is committed to developing precision-based therapies for sarcoma, exemplified through SOT106, our investigational antibody-drug conjugate (#adc) targeting LRRC15, a clinically validated target broadly expressed across sarcoma subtypes.
👉 www.linkedin.com/posts/amy-jensen-smith-08619218_raredise…
#rarediseaseday2026 #rarediseases #rarecancers #oncologydevelopment -
SOTIO
@SOTIO
This May, Bio€quity Europe, organized by @BioCentury and #ebdgroup, heads to Prague for its 26th year. We’re thrilled to welcome the biotech community to our home city. We’ll be meeting fellow #oncology experts and showcasing how our emerging pipeline, including our #adc programs, is turning cutting-edge science into new treatment options for difficult-to-treat solid tumors. We’re eager to engage with those shaping this next wave of innovation. Learn more about this year’s event here: conferences.biocentury.com/bioequity-europe
#bioequityeurope #drugdevelopment #cancerresearch -
SOTIO
@SOTIO
Our team is heading to London to showcase our latest #adc advancements at the upcoming @World_ADC Event Series in London. Sarka Stehlikova, Director of Biologics Core Technologies, will explore next-generation bispecific ADCs, focusing on improving safety, addressing tumor heterogeneity, and translating functional preclinical data into effective therapies.
@HansonWade
#worldadc #worldadclondon #drugdevelopment #cancerresearch -
SOTIO
@SOTIO
Today, we celebrate #internationaldayofwomenandgirlsinscience. At SOTIO, women scientists play an essential role across our organization, from discovery research to translational and preclinical development for #cancer treatments. Their perspectives, leadership, and commitment are pivotal to advancing innovative, patient-focused therapies and turning scientific insight into real-world impact. Their work helps move promising science forward and brings us closer to delivering meaningful new treatment options for patients.
#womeninscience #womeninstem #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
#worldcancerday reminds us of the importance of innovation and collaboration in advancing care for patients everywhere. SOTIO is committed to developing novel therapies for patients with #solidtumors, including next-generation #adcs like SOT106 for the treatment of soft tissue sarcoma and osteosarcoma and SOT109 for the treatment of colorectal and GI cancers. By creating more precise and effective treatment options, we aim to improve outcomes and expand possibles for those living with cancer. Learn more about our work here: sotio.com/pipeline/sotio-biotech-pipeline
#cancerresearch #oncologyinnovation #drugdevelopment #unitedbyunique -
SOTIO
@SOTIO
January was a strong start to the year for our CEO Radek Spisek and SOTIO BD team, with valuable discussions across the #biotech and #oncology communities at the @jpmorgan Global Healthcare Conference, the @InformaConnect #biotechshowcase, and the @SachsAssociates Oncology Innovation Forum.
Thank you to everyone who met with us - we look forward to continuing these conversations and exploring future collaboration opportunities. Take a look at some highlights below.
#jpm26 #sachs_oif #drugdiscovery #biotechpartnering #oncologyinnovation -
SOTIO
@SOTIO
We’re looking forward to the upcoming #pragueonco conference (pragueonco.cz/en/), where we’ll join conversations on the latest advances in #oncology research. Jitka Fucikova, Senior Scientist, will co-chair and participate in a discussion on emerging insights into immune surveillance in ovarian cancer, exploring how innate and adaptive immune cells work together to shape antitumor responses.
#oncologydevelopment #cancerresearch #jsmeppf -
SOTIO
@SOTIO
We are excited to share this collaborative publication in @NaturePortfolioCommunications, led by our partners at the @UniBasel_en alongside the SOTIO research team.
The study shows that ovarian cancer dramatically alters the omentum, a fatty tissue in the abdomen, when it spreads there. By mapping individual cells in healthy and cancer-affected tissue, researchers found that the cancer reprograms the omentum to support tumor growth.
We thank our academic collaborators and all contributing institutions for their scientific excellence and dedication in advancing cancer research: @UniSpitalBasel, @ETH_en, @ISBSIB, @CharlesUniPRG
Read the full text here: pubmed.ncbi.nlm.nih.gov/41397972/
#oncologyresearch #ovariancancer -
SOTIO
@SOTIO
We’re heading to San Diego for PepTalk: The Protein Science and Production Week. Sarka Stehlikova, Director of Biologics Core Technologies, will share how SOTIO is developing next-generation bispecific #adcs. She will explore strategies focused on fine-tuning bispecific approaches to improve efficacy while reducing on-target toxicity, addressing tumor heterogeneity, and bridging functional in vitro findings with in vivo performance.
We’re excited to further the discussion on pushing the boundaries of ADC innovation and SOTIO’s leadership in driving these advances forward.
#chipeptalk #peptalk2025 #adcinnovation #oncologyresearch -
SOTIO
@SOTIO
The Patent Litigation Europe Summit is around the corner, and our Head of IP, Christoph Rehfuess, will be speaking. Christoph’s panel discussion will examine Bolar exemptions and safe harbor provisions, with a focus on how evolving case law and legislative reform are influencing patent enforcement, timing of injunctions, and litigation risk.
Check out more from Christoph: www.linkedin.com/posts/christoph-rehfuess-80114518_patent…
#litigationsummit #biotechnology #jsmeppf -
SOTIO
@SOTIO
Are you motivated by the opportunity to contribute to innovative methods for developing novel cancer treatments? We’re looking for a Junior Scientist to join our Biologics Core Technologies (BCT) lab at SOTIO. This is an exciting chance to become part a of our team that is responsible for designing our investigational drug candidates.
Details about the position can be found below:
www.linkedin.com/jobs/search/?currentJobId=4358195699&key…
and on our website: sotio.com/career/junior-scientist-bct-1
To learn more about our culture and what it’s like to work at SOTIO, check out the video below.
#biotechnology #oncologyresearch #hiring #lifesciencehiring #jsmeppfThis media couldn't be displayed. See it on the original post. -
SOTIO
@SOTIO
#jpm26 is approaching, and we look forward to meeting investors and pharmaceutical partners to explore collaborations on our next-generation therapies for hard-to-treat #cancers. Please reach out to schedule a meeting.
@jpmorgan
#jpm2026 #healthcareinnovation #oncologydevelopment -
SOTIO
@SOTIO
This holiday season, SOTIO and SCTbio employees came together to support two palliative care organizations making a meaningful difference for patients and families. Through our holiday #charity campaign, we donated almost $4,000 USD, with corporate matching set to double the impact. The organizations supported, both nominated and voted for by our colleagues, were @CestaDomu, our long-term partner providing mobile hospice and palliative care to terminally ill patients and their families, and Home Hospice Mezi břehy, which offers professional palliative care to adult and pediatric patients in their home environment.
This year’s charity initiative also included a team-building activity where our colleagues created their own paintings. One artwork was donated to a special charity auction, helping us raise an additional significant contribution for both organizations.
Learn more about the essential work these organizations do here: www.cestadomu.cz/en hospicmezibrehy.cz
A heartfelt thank you to all our team members for their generosity and commitment to making a positive impact. Check out some snapshots below!
#socialresponsibility #socialimpact #jsmeppf -
SOTIO
@SOTIO
We’re looking forward to presenting at @World_ADC’s upcoming ADC Pharmacokinetics and Clinical Pharmacology Summit. Zuzana Antosova, Director of Bioanalysis and Pharmacokinetics, will discuss how #adc stability shapes safety outcomes and informs the translation of preclinical stability data into human pharmacokinetic predictions. She’ll also explore the role of species differences in degradation assessment and model selection and highlight how robust preclinical data can enhance the accuracy of human PK modeling.
#worldadcevents #adcinnovation #oncologyresearch -
SOTIO
@SOTIO
We’re joining the upcoming @VIBTrainConf on “Tumor Heterogeneity, Plasticity and Therapy” in Leuven, Belgium. This meeting brings together leading researchers exploring how tumor cell diversity and microenvironmental interactions shape cancer progression and therapy resistance. Anna Bock, Scientist, will present our latest findings on natural killer (NK) cell biology and their role in anticancer immunity in #ovarian #carcinoma. Laura Horvathova, Scientist, will highlight Integrative molecular and spatial analysis of intratumoral tertiary lymphoid structures and insights into immunotherapy response.
#vibconf #cancerresearch #oncologyresearch -
SOTIO
@SOTIO
We’re heading to London to share new insights into the tumor immune microenvironment and novel immune modulatory approaches at the upcoming @myESMO Immuno-Oncology Congress. Artemis Angelidou, Scientist, will present data on how NKG2A inhibition enhances the crosstalk between NK and CD8+ T cells to strengthen anticancer immunity in ovarian carcinoma. Barbora Tunková, Scientist, will share an integrative and spatial analysis of tertiary lymphoid structures within tumors, providing insights into mechanisms driving response to #immunotherapy.
#esmoimmuno25 #immunooncology #cancerbiology -
SOTIO
@SOTIO
We have an exciting calendar of events at #jpm26 in January. You can meet us at:
• The @jpmorgan Global Healthcare Conference, attended by our CEO and BD team
• The @informaconnect #biotechshowcase satellite event, attended by Martin Vodak
• The @SachsAssociates Oncology Innovation Forum (#sachs_oif), where Norbert Prenzel is joining a panel focused on the next generation of #adcs in #oncology
It will be an energizing start to 2026, with valuable opportunities to connect across the industry. If you would like to arrange a meeting with our BD team, please reach out to partnering@sotio.com.
#drugdiscovery #biotechpartnering #oncologyinnovation -
SOTIO
@SOTIO
At #ctos2025 we presented new preclinical data on SOT106 #adc supporting its best-in-class potential to treat major subsets of #osteosarcoma and soft tissue #sarcomas. Our data showed high therapeutic index and excellent activity across a broad range of LRRC15 target expression.
Read our press release to learn more: sotio.com/news-publications/news/sotio-presents-positive-…
@ctosociety -
SOTIO
@SOTIO
We are presenting SOTIO’s advanced preclinical stage ADC programs, SOT106 and SOT109, at the LSX conference next week. Jens Hennecke and Norbert Prenzel will be available during the London Life Sciences Week to discuss the opportunity to invest and collaborate on the development of these programs for difficult-to-treat solid tumors like colorectal cancer and #sarcoma.
#investival #londonlifesciencesweek #llsw2025 #healthcare #cancerresearch #oncology -
SOTIO
@SOTIO
How do we unlock better treatments for #sarcoma patients? At this year’s @ctosociety meeting, we will present new preclinical data on SOT106, our investigational #adc targeting LRRC15. Lenka Palova Jelinkova, Director of Translational Science, will present our latest IND-enabling data on SOT106 showing best-in-class potential in soft tissue sarcoma and osteosarcoma — areas of high unmet need. Read more in today’s press release: www.sotio.com//news-publications/news/sotio-presents-posi…
#ctos2025 #immunooncology #drugdevelopment -
SOTIO
@SOTIO
Today we announced the appointment of Dr. Vivi Boura as Chief Medical Officer. Dr. Boura has been a driving force behind our clinical development efforts and has played a pivotal role in advancing our investigational #adc programs. Her leadership and clinical vision will continue to be instrumental as we progress our growing portfolio of next-generation #adcs and #immunotherapies. Read more in today’s announcement: sotio.com/news-publications/news/sotio-announces-promotio…
#biotechnology #leadershipannouncement #drugdevelopment #oncologyresearch -
SOTIO
@SOTIO
We will present new preclinical data on several of our investigational therapies at the @World_ADC Event Series in San Diego and #pegseurope in Lisbon, including SOT106 and SOT109 — two next-generation #adcs with potential in difficult-to-treat solid tumors. Read more in today’s press release: sotio.com/news-publications/news/sotio-to-present-data-hi…
#worldadc2025 #pegs2025 #immunooncology #targetedtherapies #drugdevelopment -
SOTIO
@SOTIO
Jens Hennecke and Norbert Prenzel will attend #bioeurope next week in Vienna. As we continue to advance our pipeline of immunotherapies and #adcs, we’re excited to meet with potential partners and investors to explore opportunities for collaboration and growth. If you’re attending, let’s connect.
@EBDgroup
#bioeurope2025 #biotechpartnering #oncologyinnovation #cancertherapeutics -
SOTIO
@SOTIO
The need for more precise and effective #cancer therapies continues to drive innovation in #adcs. SOT106, our novel ADC targeting LRRC15, is designed to treat sarcomas and other LRRC15-positive solid tumors with high unmet need.
Backed by strong preclinical data, SOT106 demonstrates best-in-class potential with broad therapeutic reach and a favorable safety profile. Learn more about SOT106 here: sotio.com/pipeline/antibody-drug-conjugates/sot106
#biotechnology #drugdevelopment #cancerresearch #oncology -
SOTIO
@SOTIO
This week, our Deputy CMO Vivi Boura and other colleagues are heading to @myESMO congress in Berlin. We look forward to connecting with fellow oncology innovators and sharing how our pipeline of next-generation immunotherapies and #adc programs are advancing treatment options for patients with difficult-to-treat solid tumors. Learn more about our pipeline here: sotio.com/pipeline/sotio-biotech-pipeline
#esmo2025 #biotechnology #oncologyresearch #cancertherapy -
SOTIO
@SOTIO
Fierce Biotech Week 2025 brought together leaders from across the industry for thoughtful discussion and moments to collaborate in Boston. Robyn Hunter, Chief Financial Officer, joined industry leaders to discuss how biotech and pharma companies can design partnerships that stand the test of time.
Check out some photos below from the event!
@FierceBiotech @LifeSciEvents
#biotechnology #fiercebiotechweek2025 -
SOTIO
@SOTIO
Christoph Rehfuess, Head of IP, will be speaking at the upcoming Life Sciences Strategy Summit on IP & Exclusivity in Munich.
His presentations will cover the Bolar exemption, exploring differing interpretations across jurisdictions, as well as recent EPO Board of Appeal decisions affecting IP in the life sciences.
#lifesciencesstrategy #healthcareinnovation #intellectualpropertylaw -
SOTIO
@SOTIO
Today we announced the appointments of Dr. Amy Jensen-Smith as Chief Scientific Officer and Dr. Ulrich Moebius as Chief Development Officer.
Their combined expertise will support the continued progress and expansion of our portfolio of next-generation #adcs and #immunotherapies.
Read more in today’s release: sotio.com/news-publications/news/sotio-strengthens-leader…
#biotechnology #leadershipannouncement #drugdevelopment #oncologyresearch -
SOTIO
@SOTIO
Next week, Robyn Hunter, Chief Financial Officer at SOTIO, will speak on a panel at @FierceBiotech Week. She’ll join fellow industry leaders to discuss how #biotech and pharma companies can build partnerships that create lasting value.
If attending, be sure to stop by!
www.linkedin.com/posts/robyn-hunter-cfo_meetmeat-fiercebi…
@LifeSciEvents
#fiercebiotechweek2025 #alltogether #biotechnology -
SOTIO
@SOTIO
The SOTIO research team, led by Anna Fialova, Senior Scientist, have published a study in @jitcancer. Their study explores the role of regulatory immune cells in the tumor microenvironment of cervical cancer, showing that high levels of regulatory T cells and myeloid-derived suppressor cells in tertiary lymphoid structures are associated with poor overall survival. Read the full article here: www.idnes.cz/zpravy/domaci/rakovina-lek-vyvoj-molekula-la…
#biotechnology #oncologyresearch #drugdevelopment #cancertherapeutics #jsmeppf -
SOTIO
@SOTIO
SOTIO will attend the upcoming SAGO 2025: State of the Art Gynecologic Oncology Congress in Prague. Our CEO, Radek Spisek, will offer his perspective on the current #immunotherapy landscape and future directions of cancer care. Jitka Fucikova, Senior Scientist, will follow with a discussion exploring the underlying mechanisms and scientific rationale driving these approaches.
#sago2025 #gynecologiconcology #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
Next week we will join fellow industry experts at Europe’s largest biologics event, the Festival of Biologics (@festofbiologics). Interested in setting up time to connect and learn about our leading #adc programs? Reach out to us. Jens Hennecke, Chief Business Officer, will be in attendance.
#festivalofbiologics #festofbiologics
#cancerresearch #drugdevelopment -
SOTIO
@SOTIO
This World Cancer Research Day, we stand alongside the global research community dedicated to developing innovative therapies and improving outcomes for patients. Our team is advancing a pipeline of novel therapies designed to act on highly promising #oncology targets. #adcs SOT106 and SOT109, and IL-15 immunocytokine SOT201, represent a new generation of targeted #cancer therapies. Learn more here: sotio.com/pipeline/sotio-biotech-pipeline
#worldcancerresearchday #immunotherapy #cancerresearch #immunooncology -
SOTIO
@SOTIO
Now in Phase 1 clinical trial, SOT201 is a next-generation PD-1-targeting immunocytokine designed to go beyond traditional checkpoint inhibitors. It combines PD-1 blockade with IL-15 immune stimulation to activate the immune system against solid tumors, including those resistant to current immunotherapies. Learn more: clinicaltrials.gov/study/NCT06163391
#biotechnology #immunotherapy #drugdevelopment #oncology -
SOTIO
@SOTIO
What if we could safely target one of the most consistently expressed antigens in #colorectalcancer?
One of our investigational #adcs, SOT109, is designed to unlock the potential of CDH17 – expressed in over 90% of #crc cases.
We’re now advancing SOT109 through preclinical studies, as we work to redefine what’s possible in colorectal cancer treatment. Read more: sotio.com/news-publications/news/sotio-reports-promising-…
#biotechnology #cancertherapy #drugdevelopment -
SOTIO
@SOTIO
SOTIO is heading to two key partnering events this month to advance collaboration in #oncology drug development. We’ll be at @HansonWade’s ADC & Novel Conjugates Partnering & Investment Summit and @BioCentury’s Grand Rounds Europe to exchange ideas, explore new partnerships, and connect with leaders across pharma and investors. If you’ll be there too — let’s meet!
#oncology #businessdevelopment #adc #cancerresearch #biocenturygrandrounds -
SOTIO
@SOTIO
We’re looking forward to showcasing our latest #immunotherapy innovations at @CancerResearch’s 9th Intl. #cicon2025 meeting, “Translating Science Into Survival,” next month. Artemis Angelidou, Scientist, will present on our NK cell platform, while Ann Fialová, Senior Scientist, delivers our findings on tertiary lymphoid structures in HPV-induced cancers.
Read more about our pipeline here: sotio.com/pipeline/sotio-biotech-pipeline
#cicon2025 #immunooncology #biotechnology #cancerresearch -
SOTIO
@SOTIO
How do you choose the right target to unlock the full potential of a bispecific therapy? Joachin Kiemle-Kallee, Senior Medical Director at SOTIO, will participate in an upcoming panel at the @HansonWade World Bispecific Summit titled “Strategic Target Selection for Optimizing Bispecific Design and Function.”
The discussion will explore how aligning target biology, mechanism of action, and molecular format is critical to therapeutic success.
#biotechnology #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
Next month Christian Frantz, Ph.D., our IP Manager, will share insights on intellectual property strategies in drug development at the @BrainLinx European Intellectual Property Forum. Dr. Frantz will share proactive steps to protect one’s intellectual property during B2B drug development.
#biotechnology #brainlinx #cancerresearch #oncologydevelopment #jsmeppf -
SOTIO
@SOTIO
Congratulations to Jitka Palich Fucikova, Ph.D., one of our Senior Scientists who has been named one of the 2025 @EFIS_Immunology Eastern Star Awardees! Jitka and her team were recognized for her cutting-edge research on the spatial interplay between #cancer and immune components, a key insight to improve the effectiveness of immunotherapy in both “cold” and “hot” tumors. Congratulations!
#biotechnology #cancerimmunotherapy #jsmeppf -
SOTIO
@SOTIO
#worldlungcancerday recognizes the urgent need for innovation in treating #lungcancer, the leading cause of cancer-related deaths worldwide. Lung cancer, while making up only about 12% of new cancer diagnoses, is projected to cause roughly one in five cancer deaths in 2025, making it the deadliest solid tumor. At SOTIO, we’re deeply committed to advancing innovative therapies that address the significant unmet medical need across a wide range of solid tumors, including those that are treatment-resistant or have limited therapeutic options.
#biotechnology #lungcancerresearch #cancerresearch #oncology #jsmeppf -
SOTIO
@SOTIO
Our talented interns have shown exceptional dedication, passion, and insightfulness during their time with Team SOTIO this year. Their efforts have been greatly appreciated in advancing our R&D initiatives and driving forward innovation in cancer treatment. We’re grateful for their enthusiasm and the meaningful impact they’ve made across our organization.
Thank you all for being a part of our mission!
#nationalinternday #biotechnology #biotechinterns -
SOTIO
@SOTIO
The global antibody-drug conjugate (#adc) market is rapidly expanding due to increasing cancer cases, technological breakthroughs, and a heightened demand for targeted therapies.
SOT106 and SOT109, our two potentially best-in-class ADCs, have demonstrated robust anti-tumor activity and favorable preclinical profiles, reinforcing the potential of SOTIO’s ADC platform to address a broad range of solid tumors. Read more: sotio.com/news-publications/news/sotio-reports-promising-…
#biotechnology #drugdevelopment #cancerresearch -
SOTIO
@SOTIO
Sarcoma treatment remains a critical unmet need in #oncology, with limited treatment options for patients.
We’re advancing SOT106, a next-gen #adc that delivers potent payloads directly to tumors while saving healthy tissue. SOT106’s promising preclinical data was featured in an oral presentation at #aacr25.
Learn more: sotio.com/pipeline/antibody-drug-conjugates/sot106
#sarcomaawarenessmonth #biotechnology #drugdevelopment #oncologyresearch #sarcomaawarenessmonth -
SOTIO
@SOTIO
Last week employees from our U.S. and European offices reunited for our yearly SOTIO and SCTbio Day, an event dedicated to connection, creativity, and collaboration. Events like these remind us that innovation is built not only in the lab, but in the culture we create as a team. Thanks to everyone who joined, had fun and helped make it a success!
#biotechnology #jsmeppf -
SOTIO
@SOTIO
At SOTIO, we are advancing multiple technology platforms to develop potent therapies for patients with solid tumors. Next week at the @EACRNews Congress, we will present four posters that share insights into tumor immunology and its relevance for #cancer immunotherapy. Together these presentations reflect our continued commitment to translating deep immunological insights into impactful cancer treatments for patients.
Read more about the conference here: 2025.eacr.org
#eacr2025 #biotechnology #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
We will attend the @IAmBiotech convention in Boston next week! Interested in meeting? Reach out to us.
#bio2025 #biotechnology #cancerresearch #drugdevelopment -
SOTIO
@SOTIO
We’re proud to share that for the 8th time, SOTIO and SCTbio colleagues participated in ‘Bike to Work’ month and chose a healthier, more sustainable way to commute. This year, 26 participants cycled an impressive 8,831 km, helping to prevent roughly 1,413 kg of CO2 emissions and supporting a greener environment. Learn more here: www.linkedin.com/feed/update/urn:li:activity:733671426621…
Thanks to everyone who joined the ride this year!
#sustainability #biketowork #jsmeppf -
SOTIO
@SOTIO
We’re developing the next generation of potent immunotherapies for patients with solid tumors. In honor of #cancerimmunotherapy Month, we are spotlighting one of the unique approaches we’re taking to activating the immune system to fight #cancer: immunocytokines. Our next-generation PD-1-targeting immunocytokine SOT201 is progressing through a Phase 1 study. SOT201 is designed to reinvigorate exhausted T cells in tumors, as this video shows.
In addition to SOT201, we’re advancing a deep pipeline of cutting-edge ADCs and CAR-T cell therapies. All these approaches are informed by our deep expertise in cancer biology and therapeutic development.
Explore our full pipeline: sotio.com/pipeline/sotio-biotech-pipeline
#biotechnology #cancerimmunotherapy #immunooncology #cancerresearch #drugdevelopmentThis media couldn't be displayed. See it on the original post. -
SOTIO
@SOTIO
We’re looking forward to attending this year’s @ASCO conference in Chicago. We’re proud to be part of this global gathering of researchers, clinicians, and innovators working to shape the future of #cancer treatment. If you’ll be on the ground at ASCO, please reach out to connect with Radek Spisek, our CEO, and members of our clinical team who will be available to meet up throughout the conference.
#asco2025 #biotechnology #cancerresearch -
SOTIO
@SOTIO
In a newly released Q&A with Discover Pharma, Martin Steegmaier, Chief Scientific Officer at SOTIO, discusses SOT109, our investigational antibody-drug conjugate targeting CDH17.
Read the full article here: discover-pharma.com/sotios-sot109-targets-cdh17-in-colore… -
SOTIO
@SOTIO
On #clinicaltrialsday, we’re proud to recognize the dedicated professionals on Team SOTIO who are driving innovation in #cancer treatment through clinical research. Hear from our colleagues on what their work in clinical research means to them and what drives their commitment to advancing innovative therapies.
We’d like to thank our clinical team and broader organization for making these trials possible. And most importantly, thank you to the patients who participate.
#poweredbypurpose #biotechnology #cancerresearch #clinicalresearc -
SOTIO
@SOTIO
In a recent Q&A with @DDWJournal, our Chief Scientific Officer Martin Steegmaier, discusses how SOTIO is addressing some of the most critical challenges in #adc discovery and development. He reviews the design of bispecific ADCs, the importance of target selection, and the need for highly tailored approaches to overcome the tumor microenvironment and ensure effective payload delivery.
For additional detail on the broader momentum behind ADCs, DDW also published an overview of current developments across the field: www.ddw-online.com/adcs-show-best-in-class-potential-for-…
Read Martin’s Q&A below:
Drug Discovery World
@DDWJournal
The challenges in solid tumour targeting with bispecific ADCs
www.ddw-online.com/the-challenges-in-solid-tumour-targeti…
#bispecificantibodies -
SOTIO
@SOTIO
Next stop: Barcelona for the @EACRnews Immuno-Oncology Breakthroughs conference, where SOTIO scientists will deliver two presentations. Jana Tománková will present advanced strategies for integrative molecular and spatial analysis of intratumoral tertiary lymphoid structures for successful immunotherapy, while Irena Moserova will give updates on immunomodulatory properties of PARP inhibitors in ovarian cancer therapy.
We look forward to presenting and connecting with fellow scientists, clinicians, and translational researchers from across the immunotherapy community. Learn more about the conference here: eacr.org/conference/defenceisthebestattack2025
#eacr25 #biotechnology #cancerresearch -
SOTIO
@SOTIO
Next week we’re heading to the 25th #bioequityeurope meeting — Europe’s premier stage for rising biotechs to connect with global investors and biopharma leaders. We’re looking forward to connecting with fellow #oncology experts, and sharing how our innovative pipeline, specifically our #adc programs, are translating science into new options for difficult-to-treat solid tumors.
#bioeurope #biotechnology #adcs #cancertherapy -
SOTIO
@SOTIO
As the @AACR Annual Meeting comes to a close, we appreciate the opportunity to share the latest data from two promising antibody-drug conjugate (#adc) programs for solid tumors — SOT106 and SOT109. The interest in the presentations by our colleagues Michaela Fojtů and Nataliia Kalynovska exceeded our expectations.
It was inspiring to see so many groundbreaking innovations at the conference that have the potential to transform #cancer treatment and patients’ lives. We remain committed to pushing this research forward and sharing key developments with the #oncology community. Thank you to everyone who attended our presentations and contributed to insightful discussions.
#aacr25 #cancerresearch #biotechnology #jsmeppf -
SOTIO
@SOTIO
At the @AACR Annual Meeting this week we shared new data from our two most advanced #adc candidates, underscoring their best-in-class potential as solid tumor treatments.
In preclinical studies, SOT109 (CDH17 ADC) exhibited potent efficacy and a favorable safety profile in colorectal cancer, while SOT106 (LRRC15 ADC) demonstrated robust preclinical efficacy in mesenchymal tumors, including a broad subset of sarcomas. Read more: sotio.com/news-publications/news/sotio-reports-promising-…
#aacr25 #biotechnology #cancerresearch #antibodydrugconjugates #jsmeppf -
SOTIO
@SOTIO
Our paper on SOT201 — a novel immunocytokine combining IL-15 with PD-1 inhibition — has just been published in @jitcancer.
We report that in preclinical studies SOT201 exhibits strong anti-tumor efficacy, with several complete responses in all tested mouse tumor models. It also reactivates effector exhausted CD8+ T cells.
SOT201 is now being evaluated in our Phase 1 VICTORIA-01 clinical trial. Read the study: jitc.bmj.com/content/13/4/e010736
#biotechnology #cancerresearch #immunotherapy #oncology -
SOTIO
@SOTIO
Jitka Fučíková will be presenting a poster sharing insights on the role of tertiary lymphoid structures (TLS) and B cells in the #tumor microenvironment at the upcoming @VIBTrainConf “Immune Niches in Cancer & Inflammation” conference.
#immunotherapy #cancerresearch #oncology #vib #vibconf -
SOTIO
@SOTIO
Irena Adkins, our Director of Pharmacology, will present at the @HansonWade Tumor Models Summit Nordics in Stockholm, Sweden. She’ll discuss how preclinical models shape #oncology research, their role in advancing therapies, and the key challenges in translating findings to the clinic. Read more about the conference here: tumour-models-nordics.com
#biotechnology #cancerresearch #tumormodels2025 -
SOTIO
@SOTIO
At the upcoming @AACR Annual Meeting in Chicago, we’ll be presenting preclinical data on SOT106 and SOT109, our two most advanced #adc programs to treat solid tumors. Full presentation details are in our press release: sotio.com/news-publications/news/sotio-to-present-preclin…
#aacr25 #biotechnology #cancerresearch -
SOTIO
@SOTIO
#colorectalcancer is the 2nd deadliest cancer globally according to the @WHO. New treatments are greatly needed. Our newest #adc candidate, SOT109, targets cadherin-17 (CDH17), an antigen that is highly and homogeneously expressed in more than 90% of colorectal cancers. Learn more about our preclinical data on SOT109: sotio.com/news-publications/news/sotio-unveils-promising-…
#colorectalcancerawarenessmonth #biotechnology #antibodydrugconjugates -
SOTIO
@SOTIO
SOTIO is attending @EBDgroup’s #bioeuropespring conference this week to connect with fellow biopharma leaders and discuss advancements in #oncology. We look forward to sharing the latest updates from our solid tumor pipeline, including our portfolio of first-in-class and/or best-in-class #adcs.
#bioeurope #biotechnology -
SOTIO
@SOTIO
Today, we announced the expansion of our ADC pipeline — and our collaboration with @Synaffix — to develop two novel bispecific candidates. SOT112 and SOT113 are our first investigational bispecific ADCs for #cancer treatment. Read more in today’s release: www.sotio.com//news-publications/news/sotio-expands-adc-p…
#drugdiscovery #adc #biotechnology -
SOTIO
@SOTIO
Today we announced our first set of preclinical data on SOT109, a novel #adc targeting cadherin-17 (CDH17) at @World_ADC London. CDH17 is widely overexpressed in #crc and other GI cancers. Read more: www.sotio.com//news-publications/news/sotio-unveils-promi…
@HansonWade #worldadc #antibodydrugconjugates #cancerresearch #oncology -
SOTIO
@SOTIO
Our CSO, Martin Steegmaier, will present first preclinical data on SOT109, the newest program emerging from our #adc portfolio, at @World_ADC Event Series London. Focus will be the broad activity in CRC and excellent tolerability of this potential best-in-class molecule for the treatment of #colorectalcancer and other gastrointestinal cancers. Learn more about SOT109: sotio.com/pipeline/antibody-drug-conjugates/sot109
@HansonWade #biotechnology #cancerresearch #antibodydrugconjugates -
SOTIO
@SOTIO
In honor of Intl. Day of Women & Girls in Science, we’re spotlighting our team members, Tereza Láníčková and Barbora Tunková. In this LinkedIn article Q&A, Tereza interviews Barbora on her scientific journey.
Read more: www.linkedin.com/posts/sotio_womeninscience-womeninstem-f…
#womeninscience #womeninstem -
SOTIO
@SOTIO
Did you know that cancer remains the second-leading cause of death worldwide? We are committed to #cancerresearch to develop new treatment options for people diagnosed with solid tumors. sotio.com/pipeline/sotio-biotech-pipeline
#worldcancerday #biotechnology #cancer -
SOTIO
@SOTIO
At SOTIO, we’re dedicated to transforming cancer care through our pioneering antibody-drug conjugate (#adc) therapies. ADCs combine the precision of targeted antibodies with the power of cytotoxic payloads to selectively destroy cancer cells, saving healthy tissues and improving patient outcomes.
SOTIO’s in-house protein engineering capabilities and our recent collaboration with @Biocytogen allows us to integrate bispecific antibodies into ADCs and fine-tune the targeting of two different cancer antigens at the same time. The evolution of our ADC platform demonstrates our ongoing dedication to tackling the most challenging forms of #cancer.
Stay tuned as we continue progressing our portfolio of ADCs: sotio.com/pipeline/sotio-biotech-pipeline
#cancerresearch #biotechnology -
SOTIO
@SOTIO
Christoph Rehfuess, Head of IP, will speak at the 4th annual Pharma & Biotech Patent Litigation Europe forum this week. Christoph will join the in-house speaking faculty for a deep dive into Safe Harbor regulations, comparing their application in the USA and Europe. We look forward to connecting with fellow industry experts to discuss the latest trends, challenges, and innovations in patent litigation. #biotechnology
-
SOTIO
@SOTIO
This week we had the honor of welcoming Andreas Künne, German Ambassador to the Czech Republic, and his esteemed colleagues to SOTIO and SCTbio.
We shared insights into our advanced platforms for #cancer drug discovery & development, and discussed the opportunity for establishing a potential collaboration between #biotechs in Czech Republic and Germany together, a value we prioritize here at SOTIO across our offices.
Thank you to the team members who helped facilitate this visit, including Radek Spisek, Martin Steegmaier, Cristoph Rehfuess and Pascale Charbonnel. -
SOTIO
@SOTIO
Today, we announced the licensing of fully human antibodies from @Biocytogen to support the development of SOT109, our innovative antibody-drug conjugate (#adc) for #colorectal cancer and other #gastrointestinal (GI) cancers. We expect to initiate IND-enabling studies for SOT109 later this month. Read more in today’s release: sotio.com/news-publications/news/sotio-advances-colorecta…
-
SOTIO
@SOTIO
We will be at the @jpmorgan Healthcare Conference in San Francisco next week. Our Chief Scientific Officer, Martin Steegmaier, and Chief Business Officer, Jens Hennecke, look forward to connecting with investors and partners to share the latest updates on SOTIO’s ADC pipeline and plans for 2025.
#jpm2025 #biotechnology #oncology -
SOTIO
@SOTIO
SOTIO’s team, along with employees from SCTbio, donated more than $3,500 in our holiday #charity collection, which will be matched by corporate donations. This year, we raised funds for Zlatá rybka (Golden Fish), an organization that grants wishes to children in need, and @CestaDomu, our long-time partner of four years that provides professional services for terminally ill children and adults.
Learn more about the important work these charities do: www.zlatarybka.cz/en & www.cestadomu.cz/en
#socialresponsibility #socialimpact #jsmeppf -
SOTIO
@SOTIO
Last month we attended @HansonWade’s @World_ADC conference in San Diego, CA. Martin Steegmaier, our Chief Scientific Officer, presented on our pioneering antibody-drug conjugate (ADC) pipeline, and its ability to effectively treat solid tumors and provide transformative therapies for #cancer patients.
-
SOTIO
@SOTIO
SOTIO’s innovative work on SOT201, a PD-1-targeting immunocytokine, presented at @sitcancer meeting, was featured in a recent @DDWJournal article. Read more: www.ddw-online.com/new-data-on-pd-1-targeting-immunocytok…
#sitc2024 #cancer #jsmeppf -
SOTIO
@SOTIO
We will present at the @AACR conference on Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer in Boston, MA. Sarka Vosahlikova’s poster focuses on the role of PARP inhibitors for successful immunotherapy in #ovariancancer.
#cancerresearch #jsmeppf -
SOTIO
@SOTIO
This week, we will attend the @ctosociety 2024 annual meeting in San Diego. Our Chief Executive Officer, Radek Spisek, Ph.D., and Senior Medical Director, Vivi Boura, will connect with fellow sarcoma experts and discuss our ongoing efforts in advancing treatments for #sarcoma, such as through our DUET-01 clinical trial studying BOXR1030.
-
SOTIO
@SOTIO
Klára Plačková, our junior scientist, will present at the @IPVSociety conference in Edinburgh, UK, sharing insights on how tissue structure influences the pattern and density of immune cells that infiltrate tumors in HPV-related cancers.
#biotechnology #ipvc2024 #jsmeppf -
SOTIO
@SOTIO
We are presenting a preclinical update on SOT201, a next-generation PD-1-targeting immunocytokine, this week at @sitcancer Meeting, alongside a trial-in-progress poster on its ongoing Ph1 study. New data support SOT201’s ability to reinvigorate exhausted immune cells in PD-1 sensitive and resistant tumor models. Read more: www.sotio.com/news-publications/news/sotio-showcases-new-…
#sitc2024 #sitc24 -
SOTIO
@SOTIO
#pancreaticcancer is one of the deadliest cancers, with a 5-year survival rate of just 12%. Our Phase 1/2 CLAUDIO-01 trial is evaluating SOT102 for the treatment of pancreatic #cancer. Learn more at: sotio.com/pipeline/antibody-drug-conjugates/sot102
#cancerresearch -
SOTIO
@SOTIO
Lung cancer is the most common #cancer in men and the second most common in women. As we observe #lungcancerawarenessmonth, we reaffirm our dedication to advancing therapies for patients facing this significant unmet medical need.
#biotechnology #cancerresearch #jsmeppf -
SOTIO
@SOTIO
Next month we will be at @World_ADC in San Diego, where our CSO Martin Steegmaier will present on some of the latest progress in our portfolio of #adc candidates for solid tumors. If you’re attending, be sure to stop by his presentation, or reach out to connect.
#worldadc #cancerresearch -
SOTIO reposted
SwissEmbassyCZ
@SwissEmbassyCZ
Today, Ambassador Bucher visited @SOTIO and STCbio in Prague, and learned about innovative treatments against cancer. Thank you for the insightful day 🔬🥼 We are proud to support 🇨🇭- 🇨🇿 collaboration in R&D: Together, we strive for a healthier future! #swissczechpartnership
-
SOTIO reposted
Richard Kapsa
@RichardKapsa
Today we had the pleasure of welcoming the newest Swiss ambassador, H.E. Urs Bucher, and his colleagues to @SOTIO's Prague office. We toured our lab space, reviewed SOTIO's #cancerresearch efforts and visited our affiliate company SCTbio’s cell therapy manufacturing space.
-
SOTIO
@SOTIO
SOTIO will present three posters at the @sitcancer Meeting next month in Houston, Texas, including data supporting SOT201, a next-generation PD-1 targeting immunocytokine. More details in our press release: sotio.com/news-publications/news/sotio-announces-upcoming…
#sitc2024 -
SOTIO
@SOTIO
Our CEO, Radek Spisek, recently joined the @Labiotech_eu #beyondbiotechpodcast to discuss bispecific ADCs and their potential to revolutionize the field of #oncology, including advancements being made within the walls of SOTIO. Tune in to learn more about SOTIO’s ADC platform, including SOT102, now in Phase 1/2 clinical studies in the U.S. and Europe: podcast.labiotech.eu/1995493/episodes/15896204-bispecific…
-
SOTIO
@SOTIO
Zuzana Antosova, our Director of Bioanalysis & Pharmacokinetics, will present on the preclinical development of our anti-Claudin 18.2 ADC and its transition into clinical pharmacokinetics at the @HansonWade ADC Pharmacokinetics & Clinical Pharmacology Summit in Boston.
#biotechnology #adcs #cancerresearch -
SOTIO
@SOTIO
Coming up at the Global IP Strategy Hub’s Life Sciences Strategy Summit on IP & Exclusivity, our Head of IP, Christoph Rehfuess, will join the “Patent Quality Review: How Does this Affect your IP Strategy?” panel. The panel is focused on the concern of the life science industry regarding patent quality and an effective IP marketplace, the involvement of life science companies at the IPQC, the EPO’s efforts to enhance patent quality, and more. Learn more here: lsstrategysummit.com
-
SOTIO
@SOTIO
We’re proud to share that @JitkaFucikova, Sr Scientist, was honored with the Czech Woman (Žena Česka) 2024 Award, presented by @CNNPrima. This award recognizes women who make significant contributions to improving lives both in the Czech Republic and around the world. Jitka was also featured in @ForbesCesko’s article showcasing the 24 top female scientists. Thanks for your dedication to immunology, Jitka! Read more: forbes.cz/jsou-skvele-anbspmusite-je-znat-tady-je-novy-ro…
-
SOTIO
@SOTIO
#breastcancer is the second most common cancer worldwide, according to @IARCWHO. As we honor #breastcancerawarenessmonth, we remain committed to pioneering new treatments for patients suffering from breast #cancer and other solid tumors.
#breastcancerawareness #biotechnology #cancerresearch #jsmeppf -
SOTIO
@SOTIO
We recently concluded a six-month internship program hosting Master’s students from various institutions within the @4EUplusAlliance, facilitated by the #erasmus program. Our interns had the opportunity to participate in cutting-edge research with scientists at @CharlesUniPRG and SOTIO. Read more about the experiences they had in the lab and the impactful outcomes of their work in this article: www.ukforum.cz/en/main-categories/students/9415-a-great-i…
-
SOTIO
@SOTIO
#worldcancerresearchday is a chance to reflect on the vital role that innovation and research play in the advancement of #cancer treatments. At SOTIO, we’re developing new therapies for patients with solid tumors that have limited or no targeted treatment options.
#jsmeppf -
SOTIO
@SOTIO
This week SOTIO will join fellow industry leaders at prague.bio, a time to exchange experiences and information among professionals in Central Europe involved in the development of new therapeutic options for patients.
#biotechnology #cancerresearch #jsmeppf -
SOTIO reposted
Richard Kapsa
@RichardKapsa
Today we hosted a group of experienced professionals and students of the MBA program focused on healthcare from the @UofStThomasMN. We presented @SOTIO and our R&D activities, answered a lot of inquisitive questions and our guests visited the research laboratories.
-
SOTIO
@SOTIO
SOTIO is currently advancing three clinical studies for our investigational #cancer therapies at leading research institutions around the world. Learn more about our ongoing trials here: sotio.com/clinical-trials/clinical-trials
#biotechnology #clinicaltrials #cancerresearch #jsmeppf -
SOTIO
@SOTIO
Findings from SOTIO are featured in @AACR’s Clinical Cancer Research Journal (@CCR_AACR). This research demonstrates the impact of combining chemotherapy with immune checkpoint inhibitors, and how it can enhance ovarian #cancer treatment: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
#cancerresearch -
SOTIO
@SOTIO
We will present two posters at @C_IMT #cicon24 next week. Senior Scientist Michal Hensler will present on how chemotherapy affects immune structures to improve the benefit of T cells in treating metastatic #ovariancancer. SOTIO Scientist Jana Tománková will also present on how tertiary lymphoid structures and B cells shape T cell phenotypes in ovarian #cancer.
-
SOTIO
@SOTIO
Next week, Michal Hensler, Senior Scientist, will be at @EFIS_Immunology #eci2024 to present data on how chemotherapy influences immune structures to boost T cell effectiveness in treating metastatic ovarian #cancer.
-
SOTIO
@SOTIO
We recently announced the dosing of the first patient in our Phase 1 VICTORIA-01 study. The trial is evaluating SOT201, a novel immunocytokine designed to block PD-1 and stimulate IL-15. Drug combinations are common in #cancer treatment — but in the case of SOT201, we’ve combined 2 approaches in a single therapy. The trial is now enrolling patients at @MDAndersonNews, @UZAnieuws, @MOU_Brno, @JulesBordet, and @fnolomouc. Learn more: sotio.com/news-publications/news/sotio-announces-first-pa…
-
SOTIO
@SOTIO
We recently announced an #adc collaboration with @Biocytogen, allowing us to license multiple antibodies from Biocytogen’s RenLite platform, which we will use to develop ADC's for challenging solid tumors. Read article from @FierceBiotech to learn more:
www.fiercebiotech.com/biotech/sotio-taps-biocytogen-creat… -
SOTIO
@SOTIO
Meinhard Hasslacher, Ph.D., our Head of CMC, will participate in a webinar panel hosted by @BioProcessOL on developing complex protein-based therapies alongside other industry experts. They’ll discuss the early process development and manufacturing considerations for novel protein therapeutics, focusing specifically on #adcs and fusion proteins. Learn more and sign up to attend: event.on24.com/wcc/r/4637498/EB5BB88433B76270BCEBE948275C…
-
SOTIO
@SOTIO
#lungcancer is the leading cause of cancer-related deaths worldwide. As we observe #worldlungcancerday, we continue to press forward with research that could improve outcomes for patients with lung cancer and other solid tumors.
#biotechnology #cancerresearch #jsmeppf -
SOTIO
@SOTIO
It’s #nationalinternday in the U.S., & we are grateful to the interns who have contributed to our work at SOTIO. This summer, through the #erasmusplus program, we’ve had the pleasure of hosting a group of talented interns from universities across the EU, including @MedUni_Wien, @imc_krems and @Sorbonne_Univ_. Thank you to our senior scientist, Jitka Fucikova, for leading these students. We appreciate them and their great work.
@EUErasmusPlus #jsmeppf -
SOTIO
@SOTIO
Today we announced a research collaboration and exclusive licensing agreement with @Biocytogen to expand our #adc pipeline. This agreement enables us to license multiple fully human bispecific antibodies generated with Biocytogen’s RenLite® platform for developing next-generation ADCs targeting solid #tumors. Read more in our press release: sotio.com/news-publications/news/sotio-enters-into-multi-…
-
SOTIO
@SOTIO
Our director of pharmacology, Irena Adkins, spoke about her work at SOTIO and her love of science with Educa Magazín, a prestigious Czech magazine focused on education. She shares the surprises and satisfactions that come from a scientific career, and why she was ultimately drawn to apply her expertise to develop new medicines for #cancer.
Check out the English translation of the interview here: educamagazin.cz/2024/06/19/not-everything-works-the-way-w… -
SOTIO
@SOTIO
Sarcoma is a rare type of #cancer that develops in the bones or soft tissues. For patients with advanced, unresectable, or metastatic sarcoma, treatment options are generally limited. In our ongoing DUET-01 clinical trial we are studying the use of BOXR1030, our enhanced CAR T-cell therapy, in patients with #sarcoma and other solid tumor types in need of new treatment options. More on our website: sotio.com/clinical-trials/cell-therapies/duet-01
#sarcomaawarenessmonth -
SOTIO
@SOTIO
This month, we have initiated two new sites for our ongoing DUET-01 clinical trial in London, UK, at the @uclh and @royalmarsdenNHS. This study marks the first-in-human study of BOXR1030, an advanced CAR T-cell therapy engineered to enhance proliferation in the solid #tumor microenvironment more effectively than standard CAR T therapies. Learn more about this novel therapy in our recent press release: sotio.com/news-publications/news/sotio-presents-overview-…
-
SOTIO
@SOTIO
This week we reunited with employees from both our U.S. and European offices for our annual SOTIO & SCTbio Day, a time to recognize the progress we have made this year as a team and spend time outside with our colleagues. At Letnany Airport #prague we participated in various activities together, such as air racing, moving the statue, assembling plane parts, team swing and many others.
-
SOTIO
@SOTIO
Last month marked our team’s seventh year participating in the “Do práce na kole” (#biketowork) challenge in #prague, where many of our colleagues are based, alongside our sister company, SCTbio.
Together, the SOTIO and SCTbio teams traveled 4684 km (2910 miles) and saved 1150 kg (2535 pounds) of CO2, aiming to help create a greener and healthier #environment.
#sustainability #dopracenakole #jsmeppf -
SOTIO
@SOTIO
Immuno-oncology — activating the immune system to fight #cancer — has been revolutionary for treating blood cancer. However most solid tumors still lack effective #immunotherapy. SOTIO is focused on developing new treatments for #solidtumors, with 3 programs in clinical trials. #immune2cancer
-
SOTIO
@SOTIO
Over the weekend at #asco2024 we presented a trial-in-progress poster on our DUET-01 Phase 1/2 study of BOXR1030, a metabolically enhanced CAR T-cell therapy for the treatment of #solidtumors. View the poster here: sotio.com/news-publications/media/asco-2024-duet-01-poster
@ASCO -
SOTIO
@SOTIO
We are looking forward to attending #bio2024 next week to reconnect with peers and colleagues and share the latest on our programs across #adcs, immunocytokines and next-gen CAR-T.
#immunotherapy #biotechnology #cancer #jsmeppf -
SOTIO
@SOTIO
Today we announced the dosing of the first patient in the Phase 1 VICTORIA-01 study evaluating SOT201, a next-generation PD-1-targeting #immunocytokine. Read more in our press release: sotio.com/news-publications/news/sotio-announces-first-pa…
#biotechnology #immunotherapy #cancer #jsmeppf -
SOTIO
@SOTIO
This week at the @VIBConferences Series: “Recent insights into Immuno-Oncology,” SOTIO scientist Linn Amanda Syding will present on the influence of tissue contexture on #immune cell patterns in HPV-induced cancers.
Read more about the conference here: www.vibconferences.be/events/recent-insights-into-immuno-… -
SOTIO
@SOTIO
We will be at #asco24 next week, where we’ll present an overview of our ongoing clinical trial of BOXR1030. BOXR1030 is a next-generation CAR T-cell therapy that has shown enhanced ability to persist and proliferate in the solid tumor microenvironment, and greater infiltration of solid tumors, than conventional CAR T. Read more in our press release: sotio.com/news-publications/news/sotio-presents-overview-…
-
SOTIO
@SOTIO
Without clinical trials, the progress being made to treat serious diseases like #cancer wouldn’t be possible. On this International #clinicaltrialsday, we’re honoring the teams designing and leading SOTIO’s clinical trials across our three platforms, alongside the trial volunteers whose participation propels breakthrough #cancer research forward. Thank you!
-
SOTIO
@SOTIO
Through the ERASMUS, students who are studying #immunology at @CharlesUniPRG have chosen SOTIO to work with as part of their internship. Their skills and dedication to continued learning have made a valuable impact on our team. Learn more about this program by watching one of those interns, Şevval Ayhan from @Sorbonne_Univ_:
-
SOTIO
@SOTIO
It is #nationalcancerresearchmonth in the U.S., highlighting the importance of #research and #innovation in delivering new hope for the millions of people worldwide affected by #cancer. We are committed to developing new treatment options for solid tumors, which represent most of the hardest-to-treat types of cancer today.
Learn more about our programs: sotio.com/pipeline/sotio-biotech-pipeline -
SOTIO
@SOTIO
At #asco24 we will present a trial-in-progress poster on the DUET-01 Phase 1/2 study of BOXR1030, a next-generation GPC3-targeted CAR T-cell therapy. More in today’s release: sotio.com/news-publications/news/sotio-to-present-poster-…
@ASCO #biotechnology #cancer #immunotherapy -
SOTIO
@SOTIO
This week at #aacr24 we presented preclinical data from our BOXR platform, supporting our ability to potentially improve on CAR T-cell therapy’s efficacy in solid tumor models, as well as data on the utility of PARP inhibitors in combination with immune checkpoint inhibitors. Read the full release and view the posters on our website: sotio.com/news-publications/news/sotio-shares-new-preclin…
-
SOTIO
@SOTIO
We are on the ground in San Diego presenting new research at #aacr24. If you’re attending, be sure to check out our posters with new data from our BOXR CAR-T platform, and new scientific insights on #immunotherapy in ovarian cancer. Poster details here: sotio.com/news-publications/news/sotio-presents-new-precl…
-
SOTIO
@SOTIO
SOTIO’s research team led by Anna Fialová has published new findings in Translational Oncology. This study explores the complex connection between tissue structure and tumor-infiltrating immune cells in HPV-associated #cancer. Learn more: www.sciencedirect.com/science/article/pii/S193652332400010X #biotechnology
-
SOTIO
@SOTIO
Our recent study in @NatureComms provides a deeper understanding of the impact of #tertiarylymphoidstructures (TLSs) on intratumoral T cells. The relative lack of TLSs in #ovariancancer might explain the poor response rate to immune-checkpoint inhibitors to date as compared to other solid carcinomas, such as #nsclc. Read the full study here: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
#biotechnology #immunotherapy #cancer -
SOTIO
@SOTIO
We are attending the #bioeuropespring Conference in Barcelona this week, where we are looking forward to connecting with peers and partners throughout the European life sciences ecosystem and beyond.
#oncology #immunotherapy #biotechnology -
SOTIO
@SOTIO
At #aacr24 we will present preclinical data from our BOXR CAR-T platform and new scientific insights on #immunotherapy in ovarian #cancer. More in today’s release: sotio.com/news-publications/news/sotio-presents-new-precl…
@AACR #biotechnology -
SOTIO
@SOTIO
This International @WomensDay, we honor these and all the other talented women at SOTIO who drive our mission forward. We’re proud to #investinwomen and to reap the benefits of gender diversity every day.
#internationalwomensday #iwd2024 #jsmeppf #inspireinclusion -
SOTIO
@SOTIO
SOTIO was featured in this recent @NatureBiotech article about the exciting progress in #adcs. Our ADC platform uses cutting-edge technologies to create therapeutic candidates that can address the challenges of solid tumors. Read more: www.nature.com/articles/s41587-024-02168-5
-
SOTIO
@SOTIO
This weekend we celebrate #february11, the Int’l Day of Women & Girls in Science. SOTIO’s work to develop better cancer therapies wouldn’t be possible without the talented women who make up 2/3 of our team worldwide. Here, a few of them reflect on the role of #womeninscience:
-
SOTIO
@SOTIO
The latest issue of @AsiaBiospectrum spotlights next-generation ADCs, with insights from SOTIO CSO Martin Steegmaier about the exciting innovations on the horizon for the field.
Read more: www.biospectrumasia.com/analysis/98/23653/next-gen-adcs-a… -
SOTIO
@SOTIO
This Sunday is #worldcancerday. #solidtumors are the most common form of cancer, but many lack safe and effective therapies. At SOTIO, we’re developing next-generation #cancer therapeutics to improve outcomes for patients with solid tumors.
#biotechnology -
SOTIO
@SOTIO
Zdeněk Cakl is a Senior CMC Manager on our R&D team advancing our lead #adc candidate, SOT102, to development. Learn more about Zdeněk’s important role: www.linkedin.com/feed/update/urn:li:activity:715880594805…
#biotech #immunotherapy #jsmeppf -
SOTIO
@SOTIO
Employees from SOTIO & our sister company SCTbio donated a record $4,200 in our holiday charity collection. Our companies will double the amount and donate it to two charities caring for the sick and terminally ill, Pink Bubble Foundation and @CestaDomu. Thank you, team, for your generous giving. #jsmeppf
-
SOTIO
@SOTIO
This season, we are grateful for our employees, our clinical collaborators, and the patients & family members of patients who participate in our clinical trials. Wishing you all a joyful holiday and a peaceful new year.
#biotechnology #happyholidays #jsmeppf -
SOTIO
@SOTIO
Scientist Ann Vankerckhoven is part of SOTIO’s research team helping us shed light on new aspects of #cancer biology. Learn more about Ann: www.linkedin.com/posts/sotio_cancer-biotechnology-employe…
#biotech #immunotherapy #jsmeppf -
SOTIO
@SOTIO
SOTIO's Head of Business Development Norbert Prenzel will be at #biofit2023 this week. We look forward to connecting w/ colleagues to discuss the latest innovations in #cancer research, #adcs and #immunooncology, and how they can be leveraged to improve patient outcomes.
-
SOTIO
@SOTIO
Our team will be at #esmoimmuno23 this week to present new scientific findings on the role of tertiary lymphoid structures (TLSs) in #immunooncology. Find our full presentation details here: cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal…
#biotechnology #cancer #immunotherapy -
SOTIO
@SOTIO
Petra Jedková is the Senior Lab Manager for our Prague team. She has contributed to numerous research projects and was instrumental in designing the lab space for our new office: www.linkedin.com/posts/sotio_biotechnology-employeehighli…
#jsmeppf #biotechnology #immunotherapy -
SOTIO
@SOTIO
ICYMI, @endpts profiled our latest #adc platform expansion and interviewed Chief Business Officer Jens Hennecke. We will be working with @Synaffix to develop next-generation ADCs designed to address the challenges of #solidtumors. Read: endpoints.news/synaffix-locks-740m-adc-licensing-deal-wit…
-
SOTIO
@SOTIO
Marek Hraška is SOTIO’s Director of Clinical Project Management for our antibody-drug conjugate programs. He supports many aspects of the clinical trials including site relationships, recruitment, and data collection: www.linkedin.com/feed/update/urn:li:activity:713053977210…
#immunotherapy #biotech #jsmeppf -
SOTIO
@SOTIO
SOTIO’s team & scientists at @WeillCornell published a review of type I interferon (IFN) in #cancer biology & treatment, covering aspects of type I IFN signaling, impact on malignant transformation and tumor progression, and response to cancer therapies.
onlinelibrary.wiley.com/doi/10.1111/imr.13272?af=R -
SOTIO
@SOTIO
Last week at #sitc23, we shared the latest updates on our PD-1-inhibiting cytokine SOT201, showing in vivo efficacy and preferential targeting of PD-1 positive tumor cells, along with other data updates. View our posters here: sotio.com/news-publications/media/sotio-posters-from-sitc…
-
SOTIO
@SOTIO
SOTIO CBO Jens Hennecke & Head of BD Norbert Prenzel will be at #bioeurope in Munich next week. Please reach out if you’d like to meet to discuss collaborations on our #adcs and #cancer immunotherapies. #biotech
-
SOTIO
@SOTIO
November is both #pancreaticcancer and #lungcancer awareness month (#lcam), a reminder of the unmet need among patients diagnosed with these diseases. We are advancing antibody-drug conjugates to potentially provide a new treatment option for these and other #cancer patients.
-
SOTIO
@SOTIO
At #sitc23 this week we will be presenting new data on SOT201, our next-generation PD-1-inhibiting cytokine, and on the combination of our IL-15 superagonist nanrilkefusp alfa with T cell therapies. Learn more here: sotio.com/news-publications/news/sotio-presents-data-on-s…
#cancer #solidtumors #jsmeppf -
SOTIO
@SOTIO
Next week at #sitc23, we will be presenting new preclinical data on SOT201, our next-generation PD-1-inhibiting cytokine, and on the combination of our IL-15 superagonist with T cell therapies. If you’re attending, make sure to stop by.
@sitcancer #cancer -
SOTIO
@SOTIO
At the upcoming @myESMO 2023, our team will present about our ongoing CLAUDIO-01 #clinicaltrial evaluating the safety & preliminary efficacy of SOT102, a Claudin 18.2-targeted #adc. Details of our poster are in the online program here: cslide.ctimeetingtech.com/esmo2023/attendee/confcal_2/pre…
#esmo23 -
SOTIO
@SOTIO
Attending #worldadc San Diego? Join us for a presentation on SOT102, our novel ADC targeting Claudin 18.2, in Ph1/2 clinical testing. Director of Pharmacology Kati Räsänen will speak to our findings
today.
#immunotherapy #adc #biotech -
SOTIO
@SOTIO
We have signed a licensing agreement with @Synaffix to develop next-generation antibody-drug conjugates (ADCs) designed to address the challenges of #solidtumors. Read more: sotio.com/news-publications/news/sotio-further-expands-ne…
#biotechnews #adc #immunotherapy -
SOTIO
@SOTIO
Join us at #worldadc San Diego on 10/17 to hear the latest on our SOT102 program. SOT102 is a potent antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2).
More information on our #adc platform is here: sotio.com/pipeline/antibody-drug-conjugates/technology
#biotech #immunotherapy #jsmeppf -
SOTIO
@SOTIO
The first patients have been dosed in two combination arms of our CLAUDIO-01 study, which is evaluating our Claudin 18.2-targeting antibody-drug conjugate for treatment of #gastriccancer and #pancreaticcancer. More: sotio.com/news-publications/news/sotio-announces-first-pa…
#immunotherapy #clinicaltrials #jsmeppf -
SOTIO
@SOTIO
Our team is well-represented at the Advanced Workshop Basel to network with and learn from our European industry colleagues. The SOTIO team will present on topics including #translational science, #clinical and #regulatory issues.
-
SOTIO
@SOTIO
At last month’s Global ADC and XDC Innovation Conference in Wuxi, China, our CSO Martin Steegmaier updated our international colleagues on the progress and the latest findings in our SOT102 program. #immunotherapy #oncology #jsmeppf
-
SOTIO
@SOTIO
Tereza Lanickova will represent SOTIO at the @KeystoneSymp event “B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer Therapeutics,” presenting findings on how chemotherapy changes the immune landscape of #ovariancancer. #immunotherapy #biotechnology
-
SOTIO
@SOTIO
During the first week of October, SOTIO will attend the @AACR’s Tumor Immunology and Immunotherapy event, where we will present two posters from our scientific research in #ovariancancer. #aacr #immunotherapy #biotechnology
-
SOTIO
@SOTIO
Developing better #cancer therapies is one of the most important research efforts in medicine. #worldcancerresearchday is recognized this Sunday, and we’re honored to be part of a community working to improve treatment options for people with #solidtumors. #immunotherapy #jsmeppf
-
SOTIO
@SOTIO
SOTIO CSO Martin Steegmaier & CBO Jens Hennecke will attend the Global ADC and XDC Innovation Conference in Wuxi, China next week, presenting the latest on our SOT102 program, a Claudin 18.2-targeted antibody-drug conjugate. #immunotherapy #adc #biotechnology #jsmeppf
-
SOTIO
@SOTIO
Next week, we will be presenting two posters at #cicon23 detailing results from some of our ongoing research to understand the immune landscape of solid tumors, which helps to inform our #immunotherapy programs. #biotechnology #jsmeppf
-
SOTIO
@SOTIO
We gathered this week for an office-warming party to officially celebrate our new #prague combined lab & office space. We’re already settling in and excited about all that these new facilities will make possible. #newoffice #biotech #jsmeppf
-
SOTIO
@SOTIO
This week, Amy Jensen-Smith will deliver an oral presentation at the #cartcr Summit in #boston. She will share data on the enhanced anti-tumor efficacy of combining our BOXR #car_t with our IL-15 superagonist. car-tcr-summit.com
#immunotherapy #cancer #oncology -
SOTIO
@SOTIO
Gabriella Lukács is SOTIO’s Program Lead Clinical Data Manager for our IL-15 superagonist program. Her expertise helps us collect quality data and derive meaningful insights to advance our #immunotherapy portfolio. Read more: www.linkedin.com/feed/update/urn:li:activity:710008356764…
#jsmeppf #immunotherapy -
SOTIO
@SOTIO
Our lead #adc candidate SOT102 targets Claudin 18.2 (CLDN18.2), a promising target because it is uniquely cancer-expressed and found in a large percentage of gastric and pancreatic tumors. Learn more: sotio.com/pipeline/antibody-drug-conjugates/sot102
#biotechnology #oncology #immunotherapy -
SOTIO
@SOTIO
#dyk: #solidtumors are the most common type of #cancer – however they have seen far less benefit from #immunotherapy than blood cancers have. At SOTIO we are committed to addressing this challenge. Explore our pipeline: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
In the 2nd part of a series, our CEO Radek Spisek spoke to @BioProcessOL about how SOTIO’s antibody-drug conjugate platform uses site-specific conjugation to tailor #adcs and overcome challenges in linker technology. www.bioprocessonline.com/doc/adc-executive-roundtable-exp… #immunotherapy #biotech #oncology
-
SOTIO
@SOTIO
Our #prague team is moved into our new office & lab! We’re now together on one floor, which will spark more opportunities to collaborate and innovate, and will fuel our work to develop novel immunotherapies for #solidtumors.
#moving #newoffice #biotech #jsmeppf -
SOTIO
@SOTIO
Today is #worldlungcancerday. At SOTIO, we are advancing differentiated and novel antibody-drug conjugates with the potential to treat #lungcancer and other solid tumors.
#biotechnology #oncology #immunotherapy #adc #jsmeppf -
SOTIO
@SOTIO
Our CEO Radek Špíšek spoke with @BioProcessOL about SOTIO’s next-generation antibody-drug conjugates, and how we tailor our #adcs to specific #solidtumor types. www.bioprocessonline.com/doc/adc-executive-roundtable-per…
#cancer #immunotherapy #biotech -
SOTIO
@SOTIO
Marcel Pinto, Finance Manager, is responsible for all financial matters within our Swiss entity. His role is critical to ensuring SOTIO can continue our work to bring next-generation immunotherapies to patients with #cancer. More here: www.linkedin.com/feed/update/urn:li:activity:709029908297…
#employeehighlight -
SOTIO
@SOTIO
Our #prague team is packing up as we prepare to move to our new space at the end of July. This larger office & lab will accommodate our growing team and foster innovations that help us advance #immunotherapy approaches to treat solid tumors. We’re looking forward to settling in!
-
SOTIO
@SOTIO
SOTIO is hiring a Senior Scientist in #prague to help us shape the future of #cancer immunotherapies. This role would support preclinical development of a new generation of potent and stable antibody-drug conjugates. Apply here: sotio.com/career
#biotechjobs #adc #jsmeppf -
SOTIO
@SOTIO
July is #sarcomaawarenessmonth. There are many different types of sarcoma & very few have targeted treatments available. At SOTIO we are advancing next-generation CAR-Ts and antibody-drug conjugates to address the unmet treatment needs of sarcoma patients. #sarcoma #adc #car_t
-
SOTIO
@SOTIO
SOTIO Senior Scientist Jitka Fucikova has been awarded the title of Professor of Medical Immunology. The honor, given by Czech @prezidentpavel (left) & the Minister of Education @MikulasBek, recognizes her pioneering research and teaching in this area. Congratulations, Jitka!
-
SOTIO
@SOTIO
Tomorrow Irena Adkins, Director, Pharmacology, will present data on the additive benefit of our clinical-stage IL-15 superagonist in combination with other #cancer therapies at the Cytokine-Based Drug Development Summit.
More here: www.cytokine-based-drugdevelopment.com/seminar/nanrilkefu…
#immunotherapy #oncology -
SOTIO
@SOTIO
We are presenting at the ECDO-EATI joint annual conference. This Thursday, Jitka Fucikova, Senior Scientist, will be speaking about the clinical relevance of immunogenic cell death in #cancer.
#ecdoeati2023 #immunotherapy -
SOTIO
@SOTIO
Our teams from from the US and Europe gathered for our annual “SOTIO Day”. It was a great day of recreation and friendly competition, giving us a chance to unwind and to bond more deeply with our colleagues. We're already looking forward to next year!
-
SOTIO
@SOTIO
It’s Cancer Immunotherapy Month, an opportunity to celebrate the research SOTIO and others are doing to create improved #cancer therapies. We’re laser-focused on bringing #immunotherapy to solid tumors. Learn about our pipeline: sotio.com/pipeline/sotio-biotech-pipeline
#immune2cancer #cim23 -
SOTIO
@SOTIO
Christian Frantz is a Manager, Intellectual Property in our Business Development department, where he is in charge of SOTIO’s IP portfolio covering our antibody-drug conjugate programs.
Read more here: www.linkedin.com/feed/update/urn:li:activity:707471693400…
#employeehighlight -
SOTIO
@SOTIO
Last month, many of the SOTIO team participated in the #biketowork Challenge.
We are so proud of our colleagues who together biked 8,351 km, saved 1,077.25 kg of CO2 and contributed to a better #environment. Well done!
#gogreen #eco #dopracenakole #jsmeppf -
SOTIO
@SOTIO
We're #hiring two Senior Scientists to contribute to our exciting work on antibody-drug conjugates for #cancer. These roles, based in #prague, would support discovery and preclinical development for our next-generation ADC therapeutic candidates. Details: sotio.com/career
-
SOTIO
@SOTIO
One of our core product platforms is focused on potential best-in-class antibody-drug conjugates. Our next-generation technologies enable the design of ADCs optimized for #solidtumor activity. Learn how: sotio.com/pipeline/antibody-drug-conjugates/technology
#immunotherapy #biotech #antibody #adc -
SOTIO
@SOTIO
Clinical trials are essential for medical innovation. As we approach International #clinicaltrialsday, we’re grateful for the clinical researchers and trial volunteers who make possible our work developing novel immunotherapies to treat #cancer.
#ctd2023 #clinicaltrials #jsmeppf -
SOTIO
@SOTIO
We’re proud to have an accomplished leader like Robyn Hunter driving SOTIO’s financial strategy as we shape the future of cancer immunotherapies. Thank you Robyn!
PPF Group
@PPFGroup
In the financially challenging world of developing immunotherapies for patients with cancer, the work of executives such as Robyn Hunter, CFO of biotech company @SOTIO, is all the more important.
We talked to Robyn as the next guest in our series of videos about PPF Group.This media couldn't be displayed. See it on the original post. -
SOTIO
@SOTIO
#bioequityeurope gets underway this weekend, and our Chief Business Officer Jens Hennecke will be in Dublin to take part. We look forward to participating in these important discussions among Europe’s #biotech and investor community. #bioequity
-
SOTIO
@SOTIO
It’s #nationalcancerresearchmonth in the US, a time to appreciate the lifesaving importance of #cancerresearch. We’re proud to be part of this effort as we work to deliver the next generation of #immunotherapies for #cancer. Learn more about our approach: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
This month our SOTIO team is once again taking part in the #biketowork Challenge. Last year, we were one of more than 2,700 companies that participated in this challenge aimed at creating a more pleasant, safer, and healthier #environment! #gogreen #dopracenakole #eco #jsmeppf
-
SOTIO
@SOTIO
Our Chief Business Officer Jens Hennecke participated in a panel at #swissbiotechday earlier this week. Alongside Julian Jones @MonteRosaTx and Corinne Savill @CullinanOnco, Jens shared his insights on creating value through business development. More: swissbiotechday.ch/panel_discussion_2023/hbm-partners-2023/
-
SOTIO
@SOTIO
We will present our latest work on understanding the #tumor microenvironment at Cancer Immunotherapy and Immunomonitoring (CITIM) conference this week. Linn Amanda Syding will discuss mapping the distribution of immune cells in #cancers. View the program: www.canceritim.org/program
-
SOTIO
@SOTIO
Our oncology research team recently published an intriguing study on the anti-tumor activity of type I interferons in patients with acute myeloid leukemia. Read the paper in @SpringerNature Cell Death and Disease (@cddpress) here: www.nature.com/articles/s41419-023-05728-w
-
SOTIO
@SOTIO
SOTIO is hiring a Biomarker Scientist and Scientists for ADC and IL-15 programs. Learn more also about other open positions at SOTIO and #apply here: sotio.com/career
#jobopenings #hiring #cancer #research #science #scientist #scientistjobs #preclinical #biomarkers -
SOTIO
@SOTIO
We've joined @cddf_eu (The #cancer #drugdevelopment Forum), a non-profit organization facilitating collaboration among all actors in the oncology community such as academia, the pharmaceutical industry, regulatory authorities, HTAs, policy makers and patient advocacy groups.
-
SOTIO
@SOTIO
Nataliia Kalynovska, Ph.D., is Senior Scientist in our Preclinical Safety department where she and her team assess the safety of our drug candidates as they advance towards phase 1 clinical trials. Learn more: www.linkedin.com/posts/sotio_sotio-biotechnology-biotech-…
#sotio #biotechnology #oncology #research -
SOTIO
@SOTIO
We have recently published new scientific data on the targeting of tumor-associated macrophages for the successful #immunotherapy of ovarian carcinoma. Read the scientific paper published in the @jitcancer: jitc.bmj.com/content/11/2/e005968
#sotio #biotechnology #ovariancancer #research -
SOTIO
@SOTIO
Today we’re presenting preclinical data of our CLDN18.2-targeting ADC & its use in indications beyond gastric & pancreatic cancer at the @myESMO Targeted Anticancer Therapies Congress 2023. See the poster presented by Senior Scientist, Iva Valentova, here: sotio.com/news-publications/media/esmo-tat-2023-adc https…
-
SOTIO
@SOTIO
SOTIO’s Chief Medical Officer, Richard Sachse, talked with Simon Burns, Co-Founder & CEO of Vial, on the First in Human Podcast to discuss challenges in early clinical development. Check out the interview to learn more here: www.youtube.com/watch?v=dq7-zHpfsIA #sotio #biotechnology #oncology
-
SOTIO
@SOTIO
SOTIO’s Chief Business Officer, Jens Hennecke, will present at the @biocom Global Life Science & Investor Conference in La Jolla this week. Learn more about the event here: www.biocom.org/conferences/global-partnering-conference/ #sotio #biotechnology #biotech
-
SOTIO
@SOTIO
Emily Kuiper of SOTIO is presenting at the 6th CAR-TCR Summit Europe in London on how our newly discovered BOXR genes enhance immune cell function for the treatment of solid tumors. Learn more about BOXR & our lead candidate in development, BOXR1030 here: sotio.com/pipeline/cell-therapies/boxr1030
-
SOTIO
@SOTIO
SOTIO is hiring a CMC Manager and a Biomarker Scientist. Learn more about other open positions at SOTIO in Prague and Basel and #apply here: sotio.com/career
-
SOTIO
@SOTIO
Geoffrey Hodge from SOTIO in Cambridge, MA, shared his thoughts in a @pharmasalmanac roundtable on how our BOXR platform fits with other transformational technologies on the horizon for cell therapies. Please find the related article here: www.pharmasalmanac.com/articles/q1-what-do-you-view-as-th…
-
SOTIO
@SOTIO
SOTIO’s Medical Director of Early Clinical Development, Vivi Boura, M.D., Ph.D., is leading the clinical development of our CLDN18.2 antibody-drug conjugate (ADC) program, SOT102. Learn more about how she helps execute our CLAUDIO-01 trial here: www.linkedin.com/feed/update/urn:li:activity:702689671039…
-
SOTIO
@SOTIO
Our AURELIO-05 Phase 2 combination trial of nanrilkefusp alfa with cetuximab for colorectal cancer was featured in several leading biotech media outlets, including @BioWorld @biospace and @cure_today Read more about our trial here: www.curetoday.com/view/first-patient-with-colorectal-canc…
-
SOTIO
@SOTIO
We have initiated the Phase 2 AURELIO-05 trial of nanrilkefusp alfa (formerly SOT101) in combination with cetuximab in patients with colorectal cancer. Learn more here: sotio.com/news-publications/news/sotio-doses-first-patien… #sotio #biotechnology #biotech #oncology #immunotherapy #research #cancer #crc
-
SOTIO
@SOTIO
Employees from SOTIO Biotech and SCTBio donated $4000 to our traditional holiday #charity collection. SOTIO will double the amount and donate to the charity foundations, Good Angel and Cesta Domu. Learn how you can support here: www.cestadomu.cz/en & www.dobryandel.cz
-
SOTIO
@SOTIO
Wishing everyone a safe and happy holiday season from the SOTIO team! #happyholidays #sotio
-
SOTIO
@SOTIO
#icymi we exercised our first option under our license agreement with LegoChem Biosciences for our antibody-drug conjugate (ADC) SOT106. Learn more from this @Labiotech_eu article here: www.labiotech.eu/trends-news/sotio-exercises-option-on-ad… #sotio #biotechnology #biotech #oncology #immunotherapy #research #adc
-
SOTIO
@SOTIO
Senior Scientist, Lenka Quaiserova, has worked in the SOTIO labs for seven years and has been invaluable to our progress in the understanding of the tumor microenvironment. Thank you, Lenka, for your hard work and dedication to drive innovation at SOTIO! www.linkedin.com/feed/update/urn:li:activity:700915444423…
-
SOTIO
@SOTIO
WE ARE HIRING: an experienced Senior Clinical Project Manager to join our team in Basel & a Biomarker Scientist to join our team in Prague. You can find additional information and job openings here: sotio.com/career #jobopenings #hiring #sotio #biotechnology #oncology
-
SOTIO
@SOTIO
#icymi our CBO, Jens Hennecke, talked with Beyond Biotech, the official @Labiotech_eu podcast at BIO-Europe and presented our company background and our robust clinical pipeline in development. Check out the interview here (5:10 to 13:41): www.labiotech.eu/trends-news/beyondbiotech-podcast-24/ #bioeurope2022
-
SOTIO
@SOTIO
Our IL-15 superagonist SOT101, obtained the INN name nanrilkefusp alfa from the @WHO. Learn more about the clinical development of nanrilkefusp alfa and its potential to treat #cancer patients here: sotio.com/pipeline/il-15-superagonist/nanrilkefusp-alfa #sotio #biotech #immunotherapy #oncology #solidtumors
-
SOTIO
@SOTIO
SOTIO exercises the first target-specific option with LegoChem Biosciences for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications. Learn more here: sotio.com/news-publications/news/sotio-exercises-option-f…
-
SOTIO
@SOTIO
Today, Geoffrey Hodge is presenting at the Informa Therapeutic Focus Immuno-Oncology conference discussing “BOXR: A Platform for Improving T-Cell Performance in the Solid Tumor Microenvironment." Learn more here: informaconnect.com/therapeutic-area-partnerships-oncology/
#biotech #car_t #solidtumors #immunotherapy -
SOTIO
@SOTIO
#icymi our latest translational data supporting the strong clinical potential for our BOXR T cell therapy platform were presented at @sitcancer Learn more about our metabolically enhanced CAR-T cell program BOXR1030 here: www.labiotech.eu/trends-news/sotio-reveal-cancer-treatmen… #sitc22 #cat_t #solidtumors
-
SOTIO
@SOTIO
Today Jitka Fucikova is discussing the impact of immunological configuration on disease outcome and response to immunotherapy in ovarian carcinoma. Learn more about her presentation at the 14th annual #pegseurope Summit here: www.pegsummiteurope.com/tumour-microenvironment #sotio #biotech #oncology
-
SOTIO
@SOTIO
At the @sitcancer annual meeting, we are presenting two posters highlighting why BOXR1030 CAR-T is more active in the solid tumor microenvironment and the Phase 2 trial design of AURELIO-04 evaluating SOT101 in combination with pembrolizumab. Learn more: sotio.com/news-publications/news/sotio-presents-preclinic…
-
SOTIO
@SOTIO
Researchers from SOTIO & academic collaborators explored how SOT101 induces NK cell cytotoxicity and thereby potentiates antibody-dependent cell cytotoxicity and anti-tumor activity. Latest results have been published the @FrontiersIn Immunology Journal: www.frontiersin.org/journals/immunology/articles/10.3389/…
-
SOTIO
@SOTIO
SOTIO was recently featured in this @DDWJournal article about #biotech companies based in Basel, Switzerland. Read to learn more about how we use this unique location and its environment to accelerate our #immunooncology research: www.ddw-online.com/basel-a-centre-for-ground-breaking-onc…
-
SOTIO
@SOTIO
SOTIO will present two posters at this year’s @sitcancer Annual Meeting in Boston, highlighting our Phase 2 AURELIO-04 study design & new scientific results from our BOXR T cell therapy platform. Posters will be presented on November 10-11. Learn more: sotio.com/news-publications/news/sotio-to-present-the-aur…
-
SOTIO
@SOTIO
We’re looking for an experienced Senior Clinical Project Manager as well as an eTMF Specialist to join our European team in Basel and Prague. See additional job openings and #apply here: sotio.com/career #jobopenings #hiring #sotio #biotechnology #biotech #oncology #cancer
-
SOTIO
@SOTIO
Kathy Whiteman is an Associate Director of In Vivo Pharmacology & Toxicology at SOTIO Biotech US & oversees the preclinical investigation of our BOXR T Cell therapy platform candidates. We’re lucky to have talented professionals on our team! Read more: www.linkedin.com/posts/sotio_sotio-biotechnology-oncology…
-
SOTIO
@SOTIO
Radek Spisek spoke with Matthew Pillar of @BioProcessOL about SOTIO’s Phase 2 basket study of our lead candidate, SOT101, as well as a potential inflection point in #immunooncology. Learn more here: www.bioprocessonline.com/doc/nearing-an-il-il-combination…
-
SOTIO
@SOTIO
Geoff Hodge will be presenting preclinical updates for our CAR T cell therapy candidate, BOXR1030 & our colleague, Amy Jensen-Smith will be leading a pre-conference roundtable discussion at the 7th @CAR_TCell summit. Learn more about our BOXR technology: sotio.com/pipeline/cell-therapies/boxr1030
-
SOTIO
@SOTIO
SOTIO announces that Martin Steegmaier, Ph.D., MBA, has been appointed to the position of Chief Scientific Officer. His years of expertise in #immunooncology R&D will benefit SOTIO as we advance treatments through the clinic. Learn more here: sotio.com/news-publications/news/sotio-bolsters-leadershi…
-
SOTIO
@SOTIO
SOTIO announces the appointment of Robyn Hunter to the position of Chief Financial Officer. Ms. Hunter is an accomplished CFO who brings extensive financial experience & knowledge of biotech and capital markets to SOTIO. Learn more here: sotio.com/news-publications/news/sotio-strengthens-manage…
-
SOTIO
@SOTIO
We are presenting our pipeline at the @myESMO 2022 annual meeting. Visit us at booth no. 245 in Exhibition Hall 7.2 to learn about our cancer immunotherapies: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Richard Sachse, SOTIO’s Chief Medical Officer, is presenting SOT102, our Claudin 18.2 Targeting PNU-based ADC, at the @World_ADC Conference 2022 in San Diego. Learn more about the conference here: bit.ly/3QguqLBand and our lead ADC candidate here: sotio.com/pipeline/antibody-drug-conjugates/sot102
-
SOTIO
@SOTIO
We’re looking forward to hosting a booth at this year’s @myESMO 2022 annual meeting taking place in Paris on September 9-13. Visit our booth in Exhibition Hall 7.2 to learn about the cancer immunotherapies we’re developing. Learn more about our pipeline: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
#icymi we recently initiated the AURELIO-04 Phase 2 trial of SOT101 in combination with pembrolizumab in patients with solid tumors. Check out this @Labiotech_eu article to learn more: www.labiotech.eu/trends-news/solid-tumor-tria/ #sotio #biotechnology #biotech #oncology #immunotherapy #research
-
SOTIO
@SOTIO
We’re looking for an experienced Global Regulatory Affairs Manager. Join our European team in Prague or Basel! #apply here: sotio.com/career/senior-global-regulatory-affairs-manager #jobopenings #hiring #sotio #biotechnology #biotech #oncology #cancer #immunotherapy #research #regulatory #clinicaldevelopment
-
SOTIO
@SOTIO
#icymi our U.S. CEO Geoffrey Hodge sat down with @CGT_Live to discuss our Bolt-On Chimeric Receptor (BOXR) cell therapy screening platform, which is designed to improve the functionality of engineered T cells in the solid tumor microenvironment. Lean more: www.cgtlive.com/view/geoffrey-hodge-developing-car-t-cell…
-
SOTIO
@SOTIO
Tomorrow our Director of Pharmacology, Irena Adkins, is discussing: “SOT201 is a novel targeted IL-15Rβγ agonist to alleviate PD-1- mediated immune cell suppression and potentiate anti-tumor efficacy” at the 3rd Cytokine-Based Drug Development Summit. sotio.com/pipeline/il-15-superagonist/sot201
-
SOTIO
@SOTIO
We have started the Phase 2 AURELIO-04 trial of SOT101 in combination with pembrolizumab. @MSDInvents is supplying pembrolizumab for the treatment of up to 320 patients living with multiple solid tumors. Learn more about the trial initiation here: sotio.com/news-publications/news/sotio-doses-first-patien…
-
SOTIO
@SOTIO
#icymi SOTIO’s CMO, Richard Sachse, discussed interim data from the AURELIO-03 study with @Pharmashot The data of the IL-15 superagonist, SOT101 in combination with pembrolizumab were presented at this year’s @AACR annual meeting and @ASCO Check it out: pharmashots.com/7656/pharmashots-interview-in-conversatio…
-
SOTIO
@SOTIO
Our study was published in the @AACR Clinical Cancer Research Journal. Findings suggest that while patients with highly infiltrated, “hot” ovarian carcinoma benefit from #chemo, women with “cold” ovarian carcinoma may instead require DC-based vaccination. aacrjournals.org/clincancerres/article-abstract/doi/10.11…
-
SOTIO
@SOTIO
#icymi Dr. Elena Garralda Cabanas presented promising data from the AURELIO-03 trial of our lead IL-15 superagonist, SOT101 as a monotherapy & in combination with pembrolizumab at this year’s annual @ASCO meeting. Learn more this @OncLive article here: www.onclive.com/view/sot101-displays-antitumor-activity-a…
-
SOTIO
@SOTIO
At this year’s @CellTherapyIC hybrid event, Geoffrey Hodge is discussing a presentation titled: “BOXR: A Platform for Improving T cell Performance in the Solid Tumor Microenvironment.” Learn about the event: shared.outlook.inky.com/link?domain=informaconnect.com&t=… & our BOXR technology: sotio.com/pipeline/cell-therapies/boxr-technology
-
SOTIO
@SOTIO
SOTIO US CEO, Geoffrey Hodge discussed our BOXR CAR-T cell therapy platform & moderated two panels at BioTalk in Boston, MA, an annual meeting that brings together leaders across the biopharma manufacturing community. Learn more about our BOXR technology: sotio.com/pipeline/cell-therapies/boxr-technology
-
SOTIO
@SOTIO
Once again, 31 colleagues from SOTIO & our sister company, SCTbio, participated in our annual ‘Bike to Work’ challenge. They covered 10,210.58 km (6,344.56 miles) & saved 1,329.71 kgs of CO2. Join the challenge not only in May and bike to work with our colleagues! #environment
-
SOTIO
@SOTIO
#icymi, Dr. Elena Garralda discussed promising data from our AURELIO-03 trial at this year’s @ASCO meeting. Our oral presentation slides are now available on SOTIO's website here: sotio.com/news-publications/news/data-from-sotio-s-phase-…. Check them out! #asco2022 #biotechnology #oncology #solidtumors
-
SOTIO
@SOTIO
75% of patients experience clinical benefit from the combination of SOT101 with pembrolizumab. Learn more about the data that will be discussed in the oral presentation at the @ASCO annual meeting here: sotio.com/news-publications/news/data-from-sotio-s-phase-… #asco2022 #sotio #biotechnology #oncology
-
SOTIO
@SOTIO
#icymi our CEO Radek Spisek and Geoffrey Hodge, CEO of SOTIO US discussed with @CGT_Live our three product platforms & the status of our clinical programs for the treatment of solid tumors. Check out the joint interview here: www.cgtlive.com/view/opportunities-for-car-t-cell-therapy…
-
SOTIO
@SOTIO
We’re looking for an experienced CMC Lead for our IL-15 superagonist SOT101. Join our European team in Prague or Basel! #apply here: sotio.com/career/cmc-lead-2 #jobopening #hiring #oncology #cancer #sotio #biotech #regulatory #science #clinicaldevelopment #czechrepublic #switzerland
-
SOTIO
@SOTIO
On May 16th, Rachel Yao from SOTIO & Randall Alfano from InVitria, are discussing at this year’s @ASGCTherapy annual meeting the “Importance of Chemical Definition in Yield and Reproducibility of Engineered T Cell Manufacturing Process.” Register here: annualmeeting.asgct.org
-
SOTIO
@SOTIO
Scientific data on our lead CAR T program, were published in @PLOSONE under the title “BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.” Check it out: journals.plos.org/plosone/article?id=10.1371/journal.pone…
-
SOTIO
@SOTIO
#icymi, the first patient was dosed in the Phase 1/2 CLAUDIO-01 clinical trial of our lead antibody drug conjugate, SOT102, targeting Claudin 18.2. Check out an article published in the @cure_today to learn more: www.curetoday.com/view/launching-of-early-phase-trial-may…
-
SOTIO
@SOTIO
At this year’s @ASCO Annual Meeting, Dr. Elena Garralda Cabanas will present updated interim data from the Phase 1/1b AURELIO-03 study of our IL-15 superagonist SOT101 in an oral presentation. Learn more here: sotio.com/news-publications/news/oral-presentation-of-int…
-
SOTIO
@SOTIO
The first patient has been dosed in the Phase 1/2 CLAUDIO-01 trial of SOT102, an antibody drug conjugate targeting Claudin 18.2. The trial will enroll up to 109 patients with gastric and pancreatic cancer across sites in Europe and the US. Learn more here: sotio.com/news-publications/news/sotio-initiates-claudio-…
-
SOTIO
@SOTIO
In this @biospace article, our CEO, Radek Spisek discusses the data presented at this year’s @AACR annual meeting, which highlights the oral presentation data from the AURELIO-03 Phase 1/1b combination study of our lead IL-15 superagonist SOT101. www.biospace.com/aadi-sotio-and-ikena-target-cancer-causi… #aacr2022
-
SOTIO
@SOTIO
We held an oral presentation highlighting data from the Phase 1/1b combination study of SOT101 + pembrolizumab as well as poster presentations that featured data for our preclinical candidates SOT201 & BOXR1030 at this year’s @AACR conference. sotio.com/news-publications/news/interim-data-from-the-ph…
#jsmeppf -
SOTIO
@SOTIO
In @pharmasalmanac Q1 roundtable, SOTIO’s CEO, Radek Spisek discusses our key milestones for 2022 including the initiation of the Phase 2 AURELIO-04 study with SOT101 & advancing three programs through Phase 1 (BOXR1030, SOT102 & SOT201) Check it out here: www.pharmasalmanac.com/articles/q-what-important-company-…
-
SOTIO
@SOTIO
Tomorrow, Radek Spisek, SOTIO CEO, will present our lead ADC program, SOT102 for the treatment of gastric & pancreatic cancer sotio.com/pipeline/antibody-drug-conjugates/sot102 at the 12th Annual @World_ADC summit in London, U.K. For more information on his presentation, click here: worldadc-europe.com/speaker/radek-spisek/
-
SOTIO
@SOTIO
#dyk that we’re also presenting two posters at this year’s @AACR conference? These two posters will be discussing preclinical data from our lead immunocytokine candidate (SOT201) and lead CAR T cell therapy candidate (BOXR1030). Learn more here: sotio.com/news-publications/news/sotio-announces-oral-and… #aacr2022
-
SOTIO
@SOTIO
At this year’s @AACR conference, our oral presentation will discuss interim safety and efficacy results from the AURELIO-03 dose escalation trial for our lead IL-15 superagonist, SOT101. Learn more about SOT101 here: sotio.com/pipeline/il-15-superagonist/sot101 #aacr2022
-
SOTIO
@SOTIO
We will present clinical and preclinical data at this year’s @AACR conference for our lead programs including SOT101, SOT201 and BOXR1030. Learn more about our oral & poster presentations here: sotio.com/news-publications/news/sotio-announces-oral-and… #aacr2022
-
SOTIO
@SOTIO
We’re looking for a dynamic Regulatory Project Manager to join our growing team in Basel (Switzerland) to assist in the development of innovative cancer immunotherapies. #apply here: sotio.com/career/regulatory-project-manager
#jobopenings #hiring #regulatory #sotio #biotechnology #oncology #cancer -
SOTIO
@SOTIO
Today, Geoffrey Hodge, will be discussing “BOXR: A Platform for Improving T cell Performance in the Solid Tumor Microenvironment” at the Next Generation CAR-TCR Summit in London, UK. Learn more about our BOXR technology here: sotio.com/pipeline/cell-therapies/boxr-technology
#sotio #car_t #tcell #oncology -
SOTIO
@SOTIO
On February 24, Geoffrey Hodge will be discussing “BOXR: A Platform for Improving T cell Performance in the Solid Tumor Microenvironment” at the Next Generation CAR-TCR Summit. For more information on the summit, click here: next-generation-cartcr.com/about/about-event/ or meet us in London next week!
-
SOTIO
@SOTIO
We’re looking for an experienced scientific leader for the research & development across our antibody-drug conjugate (ADC) programs. Think you’re a good match, apply here: sotio.com/career/senior-director-pharmacology & check out our other #jobopenings as well: sotio.com/career
#hiring -
SOTIO
@SOTIO
Today is #worldcancerday, a global initiative led by the @uicc. UICC and SOTIO are raising awareness for all patients as we continue to develop innovative #cancer immunotherapies (see: sotio.com/pipeline/sotio-biotech-pipeline). Learn more about this day: www.worldcancerday.org
#closethecaregap -
SOTIO
@SOTIO
We have received an open IND from the @US_FDA for SOT102. Our CLDN18.2 targeting antibody-drug conjugate will start a Phase 1 trial in patients with gastric and pancreatic cancer soon. Click here to learn more about our ADC technology and SOT102: sotio.com/pipeline/antibody-drug-conjugates/sot102
-
SOTIO
@SOTIO
Last December at our traditional Christmas charity raise SOTIO employees donated 86,293 CZK (>4K USD), exceeding totals from the previous year! SOTIO will double this amount & divide it equally between the non-profit organizations @CestaDomu & @dobryandel. www.linkedin.com/posts/sotio_sotio-charity-socialresponsi…
-
SOTIO
@SOTIO
Our research and clinical teams together with study investigators had research published in @jitcancer discussing: “Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy.” Check it out here: jitc.bmj.com/content/10/1/e003190
-
SOTIO
@SOTIO
2021 marked an amazing year of #growth & #development across not only our #clinical pipeline but our company as a whole with important announcements from major #funding to clinical collaborations. We look forward to carrying the momentum into the new year! #happynewyear2022
-
SOTIO
@SOTIO
The holiday season is upon us and the SOTIO team would like to wish everyone a happy and healthy holiday season! #happyholidays
-
SOTIO
@SOTIO
We are pleased to announce that we have filed for IND with the @US_FDA for our lead Antibody-Drug Conjugate candidate, SOT102, an ADC targeting claudin 18.2 that is targeting solid tumors. Learn more about SOT102 here: sotio.com/pipeline/antibody-drug-conjugates/sot102
#sotio #biotechnology #oncology #adc -
SOTIO
@SOTIO
Dr. Aurelienn Marabelle, M.D., Ph.D. was featured in @oncologytube discussing our #sitc21 poster presentations and the promising data lead IL-15 superagonist, SOT101 showed in patients with advanced solid tumors. Check out the interview here: oncologytube.com/video/40429/aurelien-marabelle-md-gustav…
-
SOTIO
@SOTIO
On December 16th, our Director of Pharmacology, Lenka Sadilkova is presenting at the 10th PREDiCT Tumour Models virtual summit discussing: “ADC’s Journey – Enhancing Translatability by Bridging Preclinical & Clinical Data.” Register for the event here: tumour-models.com/register/
-
SOTIO
@SOTIO
Today we announced a clinical trial collaboration with @MSDInvents. The AURELIO-04 phase 2 study will test our IL-15 #superagonist, SOT101, in combination with KEYTRUDA in patients with selected advanced/refractory solid tumors. Learn more here: sotio.com/news-publications/news/sotio-announces-clinical…
-
SOTIO
@SOTIO
On December 8, our Director of Pharmacology, Lenka Sadilkova will be presenting at the ADC Target Selection Summit discussing SOT102, our CLDN18.2-targeting antibody-drug conjugate for the treatment of gastric and pancreatic #cancer. Learn more here: adc-targetselection.com/about/about-event/
-
SOTIO reposted
-
SOTIO
@SOTIO
Today, we are pleased to announce @PPFGroup’s €280M funding of SOTIO. SOTIO plans to use this capital to advance SOT101 through phase 2 clinical trials, as well as to initiate clinical trials with three new programs for patients with solid tumors: sotio.com/news-publications/news/sotio-secures-280m-of-fu…
-
SOTIO
@SOTIO
We have received IND authorization from the @US_FDA for our next generation CAR T cell therapy candidate, BOXR1030. We are now looking forward to recruiting the first patient in early 2022. Click here to learn more about our BOXR program: sotio.com/pipeline/cell-therapies/boxr-technology
-
SOTIO
@SOTIO
Today we welcome Alise Reicin, M.D., Anthony Tolcher, M.D., FRCPC and Josep Tabernero, M.D., Ph.D. to our Strategic Advisory Board. These industry veterans will support us in our efforts to develop new immunotherapies for patients with cancer. Learn more: sotio.com/news-publications/news/sotio-strengthens-its-st…
-
SOTIO
@SOTIO
Today we significantly broaden our antibody-drug conjugate pipeline through a new multi-target collaboration with LegoChem Biosciences Inc. Learn more here: sotio.com/news-publications/news/sotio-expands-its-antibo…
-
SOTIO
@SOTIO
At @sitcancer this Saturday, we are presenting 3 posters highlighting new #clinical data on our investigational IL-15 superagonist discussing the promising safety and efficacy it has as a monotherapy & in combination with pembrolizumab. Learn more here: sotio.com/news-publications/news/sot101-shows-clinical-be…
-
SOTIO
@SOTIO
Today, our Directors of Pharmacology, Lenka Sadilkova & Irena Adkins presented data on the safety & efficacy of SOT101 & SOT102 at the 13th annual @PEGSboston Essential Protein Engineering and Cell Therapy Summit. Learn more here: www.pegsummiteurope.com #pegseurope
-
SOTIO
@SOTIO
Next week we are presenting three poster presentations highlighting new clinical data on our lead IL-15 superagonist, SOT101 at the 36th annual @sitcancer conference. Click here to learn more: sotio.com/news-publications/news/sotio-to-present-new-dat… #sitc2021
-
SOTIO
@SOTIO
Next week our Lead Scientists of Pharmacology, Lenka Sadilkova & Irena Adkins, will present data on SOT101 & SOT102 at the 13th annual @PEGSboston Essential Protein Engineering and Cell Therapy Summit. Learn more here: www.pegsummiteurope.com #pegseurope
-
SOTIO
@SOTIO
We are pleased to announce that we have filed for IND with the @US_FDA for our next generation CAR T cell therapy candidate, BOXR1030, engineered to target solid tumors like HCC and SCC. Click here to learn more: sotio.com/pipeline/cell-therapies/boxr1030
-
SOTIO
@SOTIO
This weekend, @JitkaFucikova will be participating in the 22nd @ESGO_society, presenting and discussing the topic of immunological configuration of ovarian carcinoma: the impact on disease outcome and response to immunotherapy. Click here to learn more: congress.esgo.org
-
SOTIO
@SOTIO
Our scientific team including @JitkaFucikova and SOTIO CEO, Radek Spisek had research published in @jitcancer discussing: “Immunologic configuration of ovarian carcinoma: features and impact on disease outcome.” Check it out here: jitc.bmj.com/content/9/10/e002873
#immunotherapy #jsmeppf -
SOTIO
@SOTIO
Today, Director of Pharmacology, Lenka Sadilkova is presenting in the online panel discussion for the Gaps in the Current Methodologies & Humanized Models for Therapeutic Drug In Vivo Efficacy Evaluation at the PREDiCT Innovation event. Learn more here: predict-innovation-drug-discovery.com/about-predict/
-
SOTIO
@SOTIO
The Neuron Endowment Fund awarded @cenaneuron to excellent Czech scientists yesterday. Our colleague @JitkaFucikova received the award for #research in medical sciences in the field of #cancer #immunology and #immunotherapy of cancer. Congratulations! #sotio #jsmeppf
-
SOTIO
@SOTIO
#icymi our IL-15 superagonist, SOT101 & our BOXR cell therapy platform were featured in @BioSpace as innovative #cancer immunotherapies in development for #worldcancerresearchday. Check it out here: www.biospace.com/an-in-depth-look-at-innovation-in-cancer…
#sotio #research #jsmeppf -
SOTIO
@SOTIO
Tomorrow our CMO Richard Sachse, will showcase the data from our dose escalation study of SOT101 at the Next-Gen Cytokine Therapeutics Summit. Learn about the potential of our IL-15 superagonist for the treatment of #cancer patients here : sotio.com/pipeline/il-15-superagonist/technology
-
SOTIO
@SOTIO
Tomorrow, we will be hosting a virtual booth at this year’s @myESMO conference from September 16th – September 21st. To register and view our booth click here: www.esmo.org/meetings/esmo-congress-2021/registration
-
SOTIO
@SOTIO
Luděk Sojka, CTO & CEO of SOTIO Biotech’s sister company which focuses on #celltherapy #manufacturing, discussed with @lifesci_connect how to successfully initiate a #gene therapy #supplychain strategy & the future of the BOXR1030 CAR T program. lifescienceconnect.com/090821-cto-shares-secrets-to-a-suc… #jsmeppf
-
SOTIO
@SOTIO
September is recognized as #ovariancancerawarenessmonth. We’re developing several promising immuno-oncology treatment methods across our 3 key programs & will potentially focus on ovarian cancer in future clinical trials. Learn more about our pipeline: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Our Director & Head of Discovery Research, Amy Jensen-Smith will present data for our lead candidate, BOXR1030 a next generation CAR T cell solid tumor therapy, at the 6th annual @CAR_TCell summit from August 30 to September 2. Join us by registering here: car-tcr-summit.com
-
SOTIO
@SOTIO
#dyk SOTIO is mentioned in a brand new @PPFGroup's #annualreport 30 times? You can read comprehensive report on PPF's activities in the link below. For details on SOTIO see page 64.
#sotio #biotechnology #oncology #immunotherapy #research #cancer #jsmeppf
PPF Group
@PPFGroup
We have just published our 2020 Annual Report. You can download the digital version www.ppf.cz, and hardcopies have been dispatched to media and others. Enjoy reading! PPF 3.0
-
SOTIO
@SOTIO
Amy Jensen-Smith is our director & Head of Discovery Research and leads the charge on producing novel CAR T-cell #therapies to treat #solidtumors. Amy is an exemplary leader for her team and also strives to be a role model for her two kids. Read more here: www.linkedin.com/posts/sotio_therapies-solidtumors-cancer…
-
SOTIO
@SOTIO
#dyk tomorrow we commemorate #annualmedicalcheckupday? Stage 1 cancer is highly treatable with an average 5-year survival rate of around 90% while stage 4 patients see around a 20% rate. Don’t wait for cancer, schedule your checkup today. Learn more here: wb.md/3znNVcU
-
SOTIO
@SOTIO
Yesterday was recognized as #worldlungcancerday & according to the @CDCgov it is the 3rd most common cancer in both men and women. At SOTIO we support those impacted by cancer by developing the next generation of potent immunotherapies. Learn more here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
As our Vice President of Clinical Sciences at SOTIO US, Dr. Glen Weiss is involved in #clinical direction and encourages a collaborative working environment to shape the development of our products for our #clinicaltrials. Learn more here: www.linkedin.com/feed/update/urn:li:activity:682576987910…
-
SOTIO
@SOTIO
The SOTIO research team actively participates in various worldwide #research projects. Outcomes of their work have been published in top-tier international medical journals and presented at prestigious conferences. Read some of their amazing work here: sotio.com/news-publications/publications
-
SOTIO
@SOTIO
We’re on the lookout for #scientists and other experts who are passionate about transforming the current standard of #cancer research and development to join our team. Think you’re a good match? Check out our #jobopenings and apply today: sotio.com/career
-
SOTIO
@SOTIO
Today, our Lead Scientist of Pharmacology, Irena Adkins, will be speaking at the PREDiCT conference to discuss the use, success and challenges of preclinical in vivo models with SOT101. Learn more about our IL-15 superagonist here: sotio.com/pipeline/il-15-superagonist/so-c101
-
SOTIO
@SOTIO
We are pleased to announce that our SC103 #clinical #trial has progressed to the next key part (1b). First patients in this phase started treatment at the collaborating treatment centers in Paris and Barcelona. Learn more here: sotio.com/clinical-trials/il-15-superagonist
-
SOTIO
@SOTIO
To treat #solidtumors, our #scientists are targeting #cytotoxic T-cells and natural killer cells, the two most important cells for eliciting an anti-cancer immune response. To learn more about our #oncology pipeline, click here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
One of the most actively pursued therapeutic classes in #oncology today is antibody-drug conjugates (ADCs). SOTIO’s ADC platform focuses on immunogenic cell death so that it elicits a long-lasting immune response. Learn more about our ADC tech here: sotio.com/pipeline/antibody-drug-conjugates/technology
-
SOTIO
@SOTIO
We’re on the lookout for #scientists who are passionate about transforming the current standard of #cancer #immunotherapies to join our team in Prague & support our clinical development. Think you’re a good match? Check out our #jobopenings & apply today: sotio.com/career
-
SOTIO
@SOTIO
Our Senior Manager of #technology Operations, Rachel Yao, enjoys helping her colleagues grow & reach their career goals as this inspires her to stay driven & continue to help SOTIO develop treatments for #cancer patients by overseeing our programs: www.linkedin.com/feed/update/urn:li:activity:681381070850…
-
SOTIO
@SOTIO
Our CEO, Dr. Radek Spisek, was interviewed by the @ScienceBoard to discuss our company history, current biotech pipeline and our #immunotherapies in development for the treatment of #cancer patients. Read more here: www.scienceboard.com
-
SOTIO
@SOTIO
Our antibody-drug conjugate (ADC) technology uses the #antibody to facilitate the delivery of the drug to tumors while also serving as a potent #cytotoxic agent to directly kill #tumor cells. Learn more about our science here: sotio.com/pipeline/antibody-drug-conjugates/technology
-
SOTIO
@SOTIO
In May, the 11th year of the “Bike To Work” event took place. #congratulations to Jakub Lipovsky as he covered the most km out of our 29 total colleagues that participated! Our teams combined to save 930 kilograms of CO2 & thus contributed to a #greener #city. Join us next year!
-
SOTIO
@SOTIO
With offices in the U.S., Europe and China, ever wondered where our European headquarters are located? SOTIO is located in #prague, the 'City of a Thousand Spires' and in Basel in Switzerland. Join us on a virtual tour of our Prague offices and laboratories here!
This media couldn't be displayed. See it on the original post. -
SOTIO
@SOTIO
Yesterday was #nationalcancersurvivorsday in the US, which serves as a day to celebrate those who have bravely survived the disease & also inspire the recently diagnosed patients while providing support for families. Learn more on this awareness day here: ncsd.org/about-us/
-
SOTIO
@SOTIO
Today, we presented positive data from our study evaluating our dendritic cell #vaccine, DCVAC/OvCa, for the treatment of #ovariancancer at the @ASCO conference. Our study saw improved progression free survival & improved overall survival in patients. sotio.com/news-publications/news/positive-biomarker-data-…
-
SOTIO
@SOTIO
Today marks the first day of #cancerimmunotherapyawarenessmonth and we are joining the @CancerResearch to spread awareness of cancer #immunotherapies. Learn more on the importance of this day and what these therapies could mean for cancer patients here: www.cancerresearch.org/news/2013/cri-announces-june-cance…
-
SOTIO
@SOTIO
Today, our CEO, Radek Špíšek will present our pipeline of attractive #oncology programs addressing #solidtumors, including our IL-15 superagonist, #antibody-drug conjugates, BOXR and DCVAC cell therapy programs at the @UBS Global #healthcare Conference: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Lead Scientist Pharmacology at SOTIO, Lenka Kyrych Sadilkova, Ph.D. was featured on @Oncology Tube discussing our #aacr21 poster and the promising preclinical results from a study of our #adc candidate, SOT102, for treatment of solid tumors. Watch here: oncologytube.com/video/39950/lenka-kyrych-sadilkova-phd-s…
-
SOTIO
@SOTIO
We’re on the lookout for #scientists who are passionate about transforming the current standard of #cancer #immunotherapies to join our preclinical team and support our research and clinical development. Check out our #joboppenings and apply today: sotio.com/career
-
SOTIO
@SOTIO
This year, many of our colleagues are once again taking part in the ‘Bike to work’ environmental challenge and will travel to work by bike or walk throughout the month of May. We commend and encourage our colleagues to remain active and continue promoting positive social change!
-
SOTIO
@SOTIO
We embrace and encourage an inclusive, collaborative and professional work environment across all of our offices in the U.S, Europe and China to advance our mission of translating compelling #science into #patient benefit. Learn more about us here: sotio.com/about-us/the-company
-
SOTIO
@SOTIO
#dyk we will be presenting biomarker data from our personalized DCVAC/OvCa #celltherapy platform for the treatment of #ovariancancer at this year's @ASCO? Click here for more details on our upcoming presentation: sotio.com/news-publications/news/sotio-to-present-biomark…
-
SOTIO
@SOTIO
Tomorrow, we join the @@ovariancancerco in support of #worldovariancancerday. We are committed to the fight against #cancer as we are working hard to develop new innovative treatment methods. Learn more about our efforts to cure this harmful disease here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Our senior #scientist, Anna Fialová, has been with us for more than 10 years and is currently investigating plasmacytoid #dendriticcells, the activity of the immune response and what role the #tumor environment plays in the entire cascade. Learn more here: www.linkedin.com/feed/update/urn:li:activity:679605405667…
-
SOTIO
@SOTIO
From the start, our main focus has been patients. With this in mind, our team works hard to expedite the delivery of our drug candidates including our IL-15 #superagonist, SOT101, to treat people living with #cancer. Learn more about our mission here: sotio.com/about-us/the-company
-
SOTIO
@SOTIO
Our new generation of potent and stable antibody-drug conjugates (ADCs) has a strong efficacy in direct #tumor cell killing and a good tolerability profile. Learn more about how our ADCs exert antitumor activity here: sotio.com/pipeline/antibody-drug-conjugates/technology
-
SOTIO
@SOTIO
We are excited to continue developing our BOXR platform which provides master regulatory #genes of T-cell #biology that regulate pathways essential for cell growth, proliferation and survival in the solid #tumor microenvironment. Learn more here: sotio.com/news-publications/news/sotio-acquires-rights-to…
-
SOTIO
@SOTIO
After being at SOTIO since the company was founded, Tereza Podařilová is now Head of Tumor Cells Processing and manages the production of #tumor cell lines, meaning she cares for the tumor cells and then kills them for the production of #cancer vaccines: www.linkedin.com/feed/update/urn:li:activity:679025479907…
-
SOTIO
@SOTIO
.@mattpillar from @BioProcessOL interviewed our CEO, Radek Spisek, to discuss our manufacturing capabilities, funding & company strategies to develop #cancer #immunotherapies for the treatment of our patient populations. Listen to the full interview here: www.bioprocessonline.com/doc/supercharging-an-adc-program…
-
SOTIO
@SOTIO
On Monday our Lead Scientist Pharmacology Irena Adkins presented data on our unique IL-15 agonist SO-C101 at the 9th Annual PREDiCT Meeting for #celltherapy tumor models, demonstrating optimal strategies for obtaining reliable results in preclinical anti-tumor efficacy studies.
-
SOTIO
@SOTIO
We presented positive proof of concept data from our preclinical study of SOT102, an experimental #antibody drug conjugate (ADC) therapy designed to eliminate #tumor cells in a target-specific manner at the 2021 @AACR Annual Meeting! Learn more here: sotio.com/news-publications/news/sotio-demonstrates-stron…
-
SOTIO reposted
PPF Group
@PPFGroup
"If you want to be active in biotech and you’re not established on the American market, then you’re playing second fiddle. That’s not what we want to do," says Ladislav Bartoníček. Read about e-commerce, @SOTIO and other PPF's projects in the interview for @SeznamZpravy.👇
-
SOTIO
@SOTIO
We are looking forward to presenting new preclinical data describing our #antibodydrugconjugate, SOT102, for the treatment of patients with #solidtumors at #aacr21. Learn more about our presentation here: sotio.com/news-publications/news/sotio-to-present-preclin…
-
SOTIO reposted
-
SOTIO
@SOTIO
Today, our CEO, Radek Spisek will showcase our #immunotherapy, SO-C101, for patients with #cancer at the Cytokine-based Cancer Immunotherapies Summit. Learn more about the potential of our IL-15 superagonist for the treatment of #cancer patients here: sotio.com/pipeline/il-15-superagonist/technology
-
SOTIO
@SOTIO
Along with the @PPFGroup, we have signed an agreement with @TheEIU to partner in the prestigious global Index of Cancer Preparedness project, which deals with #cancer prevention and treatment on an international scale. More here: www.linkedin.com/feed/update/urn:li:activity:678048735383…
#sotio #cancer #jsmeppf -
SOTIO
@SOTIO
Vít Budinský has been at SOTIO for more than 10 years and is now responsible for the #technology at SOTIO's clean #laboratories in which #cancer vaccines are being developed. Vit wears many hats at SOTIO, making him a multi-talented member of our team: www.linkedin.com/feed/update/urn:li:activity:678012540827…
-
SOTIO
@SOTIO
Our CTO, Luděk Sojka was featured on Cell & Gene to discuss the future of #automation in the cell therapy #manufacturing process and how C&G companies can leverage it today. View the full interview here: www.cellandgene.com/doc/c-g-therapy-manufacturing-automat… #supplychain #technology
-
SOTIO
@SOTIO
According to @ovariancancerco, #ovariancancer is the 8th most common cause of death from #cancer in women in the world. This disease is a global concern in which we are leveraging our resources and expertise to find a cure. Learn more here: sotio.com/pipeline/cell-therapies/dcvac-product-candidates
-
SOTIO
@SOTIO
According to @dosomething #cancer is the second leading cause of death globally and accounts for 1 in 6 deaths around the world. This is a devastating number in which we are working hard to reduce by advancing our #oncology pipeline. Learn more here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO reposted
PPF Group
@PPFGroup
Our dream is for @SOTIO to become a pharmaceutical company. This is one of the reasons why a number of our many colleagues from overseas did not join other biotech companies in Switzerland, Germany or France," Radek Špíšek tells @tydenikhrot.
-
SOTIO reposted
-
SOTIO
@SOTIO
We're actively searching for industry professionals in #prague to join us on our mission to improve millions of lives. Visit our careers page to learn more about our current #jobopenings here: sotio.com/career
#sotio #biotechnology #cancer #research #jobs #jsmeppf -
SOTIO
@SOTIO
Yesterday, our CTO, Luděk Sojka, was featured on @GENbio highlighting our usage of high hydrostatic pressure to develop #cancer therapies based on #dendriticcells. View the full article to learn more about our programs including our #car_t therapy BOXR: www.genengnews.com/topics/bioprocessing/putting-pressure-…
-
SOTIO
@SOTIO
Today we celebrate Radek Spisek's 3 year anniversary as our CEO! Radek was with SOTIO at its birth in 2010 and now works tirelessly to lead our team and drive our mission of treating #cancer patients. Watch us celebrate this important day with Radek:
#biotechnology #jsmeppf -
SOTIO
@SOTIO
Our lead candidate in our BOXR Program, BOXR1030, uniquely combines the BOXR-discovered GOT2 transgene, a critical enzyme involved in #cellularmetabolism, with #car_t technology. Learn more here: sotio.com/news-publications/news/sotio-acquires-rights-to…
-
SOTIO
@SOTIO
Today is #nationalcaregiversday! SOTIO commends the men and women dedicated to serving those who require long-term or hospice care. #nationalcaregiversday
-
SOTIO
@SOTIO
We are looking for new talents to join our #research team in Prague working on cutting edge #science to serve #cancer patients as a computational #biologist, scientist in biomarker and #translationalresearch and research team #scientist. See more here: sotio.com/career
-
SOTIO
@SOTIO
According to @AmericanCancer, a woman's risk of getting #ovariancancer during her lifetime is about 1 in 78. At SOTIO, we are boosting our efforts to minimize this number by developing our DCVAC/OvCa #celltherapy and other therapies targeting solid tumors: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
After our recent #donation to the charities Aufori and Donor, we were thrilled to learn how our contributions will make a difference in supporting families living in poverty or at risk of poverty and children with #cancer. Learn more here: www.linkedin.com/posts/sotio_donation-children-school-act…
-
SOTIO
@SOTIO
On #worldcancerday, we join the #cancer community to help raise awareness and provide support for #patients. View our CEO, Radek Špíšek, and Senior Scientist, Jitka Fučíková, discuss the development of our #immunotherapy to treat #cancer.
#iamandiwill #jsmeppf #weareppf -
SOTIO
@SOTIO
As proven through recent transaction of @PPFGroup with shares of NBE-Therapeutics, ADCs are one of the most promising products in targeting #cancer. View our lead ADC candidate and its unprecedented #therapeutic window and potent anti-tumor efficacy here: sotio.com/pipeline/antibody-drug-conjugates/technology
-
SOTIO
@SOTIO
Register for free to follow our Chief Technology Officer, Luděk Sojka on Cell & Gene Live discussing innovations in #celltherapy production to drive down #manufacturing costs here: event.on24.com/eventRegistration/EventLobbyServlet?target…
-
SOTIO
@SOTIO
Our Chief Technology Officer, Luděk Sojka, will speak with
Erin Harris on Cell & Gene Live to discuss #innovations in #manufacturing that can reduce both costs and risks for #celltherapy production. Click here for more on the Cell & Gene Live event: event.on24.com/eventRegistration/EventLobbyServlet?target… -
SOTIO
@SOTIO
This week, Erik Yankowsky and Rachel Yao, responsible for the development of our #boxr/CAR T platform targeting #solidtumors, traveled from our US offices to train staff at our #laboratories in Prague. More here: www.linkedin.com/feed/update/urn:li:activity:675801394623…
-
SOTIO
@SOTIO
Our Head of Pharmacovigilance, Martina Paulechová, is responsible for detecting, collecting and evaluating safety data that relates to possible side effects of products developed by SOTIO. "Our goal is to protect and ensure the safety of patients." More: www.linkedin.com/feed/update/urn:li:activity:675730463297…
-
SOTIO
@SOTIO
Are you a #scientist that is interested in working for a company that develops various immunotherapies for #cancer? If so, check out our new open positions in Prague (Czech Republic) here: sotio.com/career
-
SOTIO
@SOTIO
During the holidays, Dr. Aurélien Marabelle spoke with @OncLive to discuss preliminary findings from our #clinicaltrial examining SO-C101 in patients with advanced solid #tumors. View the interview here: www.onclive.com/view/dr-marabelle-on-preliminary-findings…
-
SOTIO
@SOTIO
We are starting off this #newyear by extending our best wishes to our colleagues, families, partners and patient population! May you all achieve your 2021 goals. View our growing pipeline here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
2020 marked a great year for the expansion of our pipeline and today, we are looking forward to amplifying our efforts in 2021 for the treatment of #solidtumors. View our latest milestones here: sotio.com/news-publications/news
-
SOTIO
@SOTIO
Big thanks to our colleagues at SOTIO who donated to our traditional Christmas charity. They donated 72 155 CZK! SOTIO will double this amount and divide it equally between the non-profit organizations Aufori and Donor. See more here: www.linkedin.com/posts/sotio_we-are-grateful-for-our-empl…
-
SOTIO
@SOTIO
Our Head of Business Intelligence, Kateřina Marenová, has been at SOTIO for ten years and develops analyses of the competitive and market environment. "Our team is just one part of the whole puzzle, with the end goal of bringing our medicine to patients." www.linkedin.com/posts/sotio_biotech-activity-67449586173…
-
SOTIO
@SOTIO
Congratulations to the NBE, @PPFGroup and @Boehringer teams on this deal worth up to €1.18 billion! We’re a proud member of PPF Group and look forward to developing our two antibody-drug conjugates (ADCs) for the treatment of #solidtumors in collaboration with NBE.
Boehringer Ingelheim
@Boehringer
#press: We’re excited to soon welcome #nbetherapeutics to Boehringer Ingelheim and look forward to jointly enhancing our cancer pipeline with novel #antibodydrugconjugates
-
SOTIO
@SOTIO
Our parent company @PPFGroup reached a major milestone after selling its stake in in NBE-Therapeutics to @Boehringer. We look forward to continuing our partnership with NBE to develop our two antibody-drug conjugates for the treatment of #solidtumors. sotio.com/news-publications/news/acquisition-agreement-wi…
-
SOTIO
@SOTIO
We're looking for innovative professionals to join our fast-growing #team. If you’re looking to work towards translating compelling #science into patient benefit with a diverse group of teammates, view our current job openings here: sotio.com/career
-
SOTIO
@SOTIO
Our financial analyst, Michal Dub, who manages the finances of our SO-C101 asset, initiated a challenge for #plasmadonations for SOTIO and the @PPFGroup employees with the intent to help patients with severe cases of COVID-19. Thank you, Michal! More here: www.linkedin.com/feed/update/urn:li:activity:673918901350…
-
SOTIO
@SOTIO
#immunotherapies targeting IL-15 signaling can be optimized to enhance their efficacy and limit off-target effects. Learn more about how our IL-15 superagonist, SO-C101, is precisely designed to do this and potentially treat #solidtumors: sotio.com/pipeline/il-15-superagonist/so-c101
-
SOTIO
@SOTIO
Our newly acquired BOXR platform, has been precisely designed to identify novel transgenes that may augment T cell #therapies to potentially improve their efficacy in treating #solidtumors. Learn more here: sotio.com/news-publications/news/sotio-acquires-rights-to…
-
SOTIO reposted
-
SOTIO
@SOTIO
We are excited to announce new encouraging interim data from its Phase 1/1b study of SO-C101 in patients with advanced solid tumors at #sitc2020. Healthcare professionals can see the link for more details: sotio.com/news-publications/news/sotio-presents-interim-d…
-
SOTIO
@SOTIO
Our team will be presenting 3 posters highlighting preclinical and clinical data on our IL-15 superagonist, SO-C101 for the treatment of advanced solid tumors at #sitc2020 to be held November 9-14, 2020. Learn more about our presentations here: sotio.com/news-publications/news/sotio-to-present-new-dat….
-
SOTIO
@SOTIO
November marks #lungcancerawarenessmonth and @Movember, an event focusing on raising awareness for men's health issues such as #prostatecancer. Learn more about our ongoing work to find potential treatments for both cancers here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
.@lcrf_org recently shared cancer patient, Lea's journey with stage 4 metastatic lung cancer. She discovered a support group and described how sharing her story with other cancer patients helped her during her ongoing battle against cancer. Read here: www.lungcancerresearchfoundation.org/for-patients/patient…
-
SOTIO
@SOTIO
Today, our chief business officer, Jens Hennecke, is presenting on our lead programs at #bio-Europe® Digital 2020. Learn more here: sotio.com/news-publications/news/sotio-to-present-at-bio-…
-
SOTIO
@SOTIO
Our CEO, Radek Špíšek, participated in an interview for the #czech edition of the @Forbes magazine to discuss the risks and costs associated with the development of new drugs and the Czech footprint in the global map of clinical development. More here: sotio.com/news-publications/media/roulette-of-life
-
SOTIO
@SOTIO
We are proud to announce Geoff Hodge has been appointed as CEO of SOTIO US. With over 30 years of experience in the #biotech industry, Geoff will greatly contribute to SOTIO US’s continued success and serve as an innovative leader for his colleagues. More: sotio.com/about-us/the-company
-
SOTIO
@SOTIO
Dept. of Immunology of Motol University Hospital (Prague) was established in 1995. Its researchers invented the idea of using immunotherapy and dendritic cells to fight #cancer. Based on this, SOTIO was created and develops various cancer #immunotherapies: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Norbert Prenzel, SOTIO’s Head of #bd and #licensing, uses his extensive professional network to connect SOTIO with potential partners around the world. “It's our core objective to find attractive business opportunities and grow our oncology portfolio." sotio.com/about-us/the-company
-
SOTIO reposted
-
SOTIO
@SOTIO
During #healthylungmonth, we would like to highlight our DCVAC/LuCa program that significantly improved survival in patients with stage IV #nsclc. Learn more about our work previous towards combatting #lungcancer here: sotio.com/news-publications/news/sotio-s-dcvac-luca-signi…
-
SOTIO
@SOTIO
On @WorldSmileDay, we would like to thank everyone at SOTIO for working towards our shared goal of achieving #scientific excellence and improving the lives of patients with #cancer. To view our leadership team, click here: sotio.com/about-us/leadership
-
SOTIO
@SOTIO
.@EuroBiotechNews recently covered our acquisition of the BOXR platform and our plans to treat solid tumors by means of next generation CAR-T cell therapies. [Subscriber content] Learn more about the BOXR platform here: sotio.com/news-publications/news/sotio-acquires-rights-to…
-
SOTIO
@SOTIO
Our CBO, Jens Hennecke, spoke with @mattpillar from @BioProcessOL about our genetically-engineered IL-15 superagonist, SO-C101, for the treatment of #solidtumors. View the full article here: www.bioprocessonline.com/doc/genetically-engineering-an-i…
-
SOTIO
@SOTIO
On Monday, we will celebrate the #biotechnology industry at the European @biotechweek. We are grateful to be a part of this industry and continue to work towards advancing our programs for the treatment of #cancer. View our pipeline here: sotio.com/pipeline/cell-therapies/dcvac-product-candidates
-
SOTIO
@SOTIO
Our CMO, Richard Sachse spoke with Hannah Balfour from @DrugTargetRev on how our IL-15 superagonist, SO-C101, can overcome some of the limitations of previous IL-15 and IL-2 targeted therapies for the treatment of #solidtumors. View the full article here: www.drugtargetreview.com/page-deleted
-
SOTIO
@SOTIO
Martin Pávek, our Supply & Operation Services Manager, handles SOTIO's complex logistics processes. "For our DCVAC product, we must deliver the patient's blood in a special temperature regime within a maximum of 30 hours from the start of collection." sotio.com/pipeline/cell-therapies/dcvac-product-candidates
-
SOTIO
@SOTIO
Today, we are leading a virtual presentation at the @MorganStanley Global Healthcare Conference highlighting our pipeline and work in #oncology. Learn more about our programs here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Located in Prague, our main facility embodies a dynamic and collaborative working environment that facilitates our mission of shaping the future of cancer immunotherapies. Learn more about SOTIO here: sotio.com/about-us/the-company
-
SOTIO
@SOTIO
A biotech company we are collaborating with for the development of new #cancer treatment methods, @NBE-Therapeutics AG, recently announced its conclusion of a $25 million cooperation agreement with a renowned US biotech company, @Exelixis. Learn more: nbe-therapeutics.com/newsroom/news-press-releases/2020/20…
-
SOTIO
@SOTIO
Today, we are virtually attending @Citi’s 15th Annual BioPharma Conference 2020. We are looking forward to engaging in conversations with leaders in the #healthcare field. To view our contributions to this field, click here: sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
This week, we were featured in one of the top biotech media outlets @FierceBiotech following the announcement of our acquisition deal with @UnumRx. View the full article here: www.fiercebiotech.com/biotech/unum-s-car-t-tech-and-resea…
-
SOTIO
@SOTIO
Check out this @endpts article covering the announcement of our acquisition deal with @UnumRx for rights to the BOXR CAR-T platform and products. Read the full article here: endpoints.news/sold-for-pennies-unum-gets-one-last-shot-a…
-
SOTIO
@SOTIO
Today, we announce that SOTIO has acquired rights to the BOXR CAR-T platform and products from @UnumRx and will create an R&D Center of Excellence in Cambridge, MA dedicated to the discovery and development of novel T cell therapies. Read more here: sotio.com/news-publications/news/sotio-acquires-rights-to… #car_t
-
SOTIO
@SOTIO
We are excited to announce that the prestigious scientific journal @jitcancer has published our research team’s new study about the role of immune infiltration in metastatic #ovariancancer. Read here: jitc.bmj.com/content/8/2/e000979
-
SOTIO
@SOTIO
#solidtumors are abnormal masses of tissue that, when malignant, pose severe threats to patients. We are working hard to develop our #immunotherapies for patients with solid tumors. To view our programs, click here sotio.com/pipeline/sotio-biotech-pipeline
-
SOTIO
@SOTIO
Our CEO Radek Špíšek, appeared on @oncologytube to discuss SOTIO's IL-15 superagonist, SO-C101, for the treatment of advanced #solidtumors. To view this interview, click here: oncologytube.com?search=sotio
-
SOTIO
@SOTIO
Dan is SOTIO’s Regulatory Affairs Specialist. His planning, preparation and submission of important documentation for SOTIO’s #clinicaltrials are critical for the success of our clinical programs. Learn about careers at SOTIO: sotio.com/career
-
SOTIO
@SOTIO
SO-C101 targets the two most important cells for driving an anti-cancer immune response: #cytotoxictcells and #naturalkillercells. It is currently being studied in patients with metastatic #solidtumors. To learn more about this #immunotherapy, click here: sotio.com/pipeline/il-15-superagonist/so-c101
-
SOTIO
@SOTIO
We are excited to announce that the prestigious scientific journal @cell_res has published our research team’s review article about the multiple roles of #calreticulin in #cancer. Find more information here: go.nature.com/3gxh9x8
-
SOTIO
@SOTIO
Join SOTIO on August 5th at 10:00 a.m. EST as we present at the inaugural LifeSci Partners Private Company Virtual Summer Symposium. To register and learn more about our pipeline, click here: lifesci.events/SummerSymposium
-
SOTIO
@SOTIO
Today, we are happy to welcome everyone to the new @SOTIO Twitter account. Follow us to stay updated on our progress towards shaping the future of #cancer #immunotherapies by translating compelling science into patient benefit. To learn more, visit here www.sotio.com











































































































































































































































































































































































































